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ABBREVIATIONS 
 
α7nAChR: α7 nicotinic acetylcholine receptor; 
AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; 
CNS: central nervous system; 
CSF: cerebrospinal fluid; 
ESBA: (S)-4-ethylsul-fonylbenzoylalanine; 
GABA: γ-aminobutyric acid; 
3-HANA: 3-hydroxyanthranilic acid; 
3-HK: 3-hydroxy-L-kynurenine; 
IDO: indoleamine 2,3-dioxygenase;  
KAT: kynurenine aminotransferase; 
KMO: kynurenine 3-monoxygenase; 
KP: kynurenine pathway;  
KYNA: kynurenic acid; 
NMDAR: N-methyl-D-aspartate receptor; 
PFC: prefrontal cortex; 
PV: parvalbumin; 
QUIN: quinolinic acid; 
SN: substantia nigra; 
SZ: schizophrenia; 
TDO: tryptophan 2,3-dioxygenase; 
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1. INTRODUCTION 
 
“We believe that interventions aimed specifically at reducing the level of kynurenic 
acid in the brain are a promising strategy for cognitive improvement in both healthy 
individuals and in those suffering from a variety of brain diseases ranging from 
schizophrenia to Alzheimer’s disease,” Dr. R. Schwarcz. 
 
 
 
Prof. Robert Schwarcz 
 
Kynurenic acid (KYNA) was discovered in 1853 by the German chemist Justus 
von Liebig in dog urine. It was the firstly identified component of the family of 
“kynurenines”, a group of metabolically related compounds which are derived from 
the essential amino acid tryptophan. In mammals, the diet represents the main 
source of tryptophan and the amino acid is metabolized via the so-called 
kynurenine pathway (KP). Recently, it has been demonstrated that a dysfunction 
of this pathway is associated with neurodegenerative and other neurological 
disorders, including psychiatric diseases such as schizophrenia (SZ, Figure 1). In 
particular, it has been demonstrated that fluctuations in the levels of kynurenines 
showed discrete effects on the nervous system and immune system (Schwarcz, 
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2004). Specifically, KYNA levels are elevated in the prefrontal cortex (PFC) of 
individuals with SZ, and normalization of KYNA concentrations in the brain has 
been suggested as an effective treatment strategy for alleviating cognitive deficits 
in this mental illness. 
In this dissertation, the effects of KYNA on extracellular GABA and glutamate 
levels in the rat striatum and prefrontal cortex (PFC), will be described. Although 
the obtained results might be also involved in the neuroprotective action of KYNA, 
their possible relevance in the ethiopathogenesis of SZ is emphasized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Kynurenine dysfunction and the common pathways in chronic 
neurodegenerative disorders (Zadori et al., 2009). 
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1.1. SCHIZOPHRENIA 
SZ is amongst the most common of the severe mental illnesses and one of the top 
ten causes of global disease burden in adults. It is a chronic psychotic disorder 
with a lifetime prevalence of about 0.7%, primarily affecting adults, and having a 
peak age of onset in the early twenties in men, and three or four years later in 
women. Based on converging evidence from a number of research disciplines, it 
has been generally accepted that both genetic and environmental factors play a 
significant role in the etiopathogenesis of SZ. However, the exact nature of these 
two main etiological factors, their pattern of interaction, and their pathogenic 
mechanisms are poorly understood, despite extensive neurobiological, clinical, 
genetic, and epidemiological research.  
SZ is formally characterized by three distinct categories of symptoms: 
 
  positive symptoms or psychotic symptoms refer to hallucinations and 
delusions, abnormality in the form of thoughts and also atypical 
psychomotor activity; 
  negative symptoms like asociality, lack of motivation and abnormality in 
social interaction; 
  cognitive symptoms, including disturbances in selective attention, working 
memory and executive functions.  
 
Even though the positive symptoms are usually the presenting and the most 
noticeable clinical features of SZ, cognitive deficits are now recognized as a core 
domain of the disease for a number of reasons (Green, 1996; Gold, 2004; Keefe, 
2007). First, it is well demonstrated that cognitive deficits are relatively stable over 
time and are also independent from psychotic symptoms. Importantly, cognitive 
dysfunctions have been found throughout the lifetime of the SZ individuals. 
Furthermore, it has been shown that patient unaffected relatives have similar 
cognitive deficits, even if milder. Finally, the severity of these deficits is more 
predictive than the positive symptoms (Green, 1996).  
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1.1.1. Cognitive deficits in schizophrenia and alterations in the prefrontal 
cortex 
It is well established that SZ-related cognitive deficits primarily affect central 
functions that depend, at least in part, on the integrity of the PFC such as working 
memory, attention and cognitive flexibility (Floresco et al., 2009; Goto et al., 2010; 
Volk and Lewis, 2010).  
The following part of this paragraph focuses on the main components of PFC 
neuronal circuitry and their possible roles in the SZ cognitive dysfunctions. 
 
 Pyramidal neurons: constitute about 75% of neurons in the cortex. They 
provide an axon projecting to other brain regions and utilize the excitatory 
neurotransmitter glutamate acting on the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPARs) and the N-methyl-D-aspartate 
receptors (NMDARs) located on their dendritic spines. Several studies have 
suggested a reduction in the number of excitatory inputs in SZ, even though 
it has not been yet elucidated the molecular mechanism(s) underlying these 
structural abnormalities (Krystal et al., 1994).  
 Interneurons: represent approximately 25% of cortical neurons and they 
use the inhibitory neurotransmitter γ-aminobutyric acid (GABA). They 
project locally by an axon and regulate the activity of the pyramidal 
neurons. Post-mortem studies on the brains of SZ individuals have revealed 
a reduced level of mRNA encoding GAD67, the enzyme responsible for the 
majority of GABA synthesis, in a subset of cortical interneurons (Hashimoto 
et al., 2008).  
 
 
1.1.1.1. Impaired cortical interneurons: relevance for cognitive dysfunctions in 
schizophrenia 
In the last few years emerged that GABA and glutamate neurotransmitters are 
critically involved in the pathophysiology of SZ (Coyle, 2004; Lewis et al., 2005; 
O’Donnell, 2012). In fact, a proper balance between the two amino acid 
transmitters is necessary for the appropriate activity of the PFC and, especially, 
adequate cognitive functions (Lewis and Moghaddam, 2006).  
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Several preclinical and clinical studies have shown that local cortical GABA 
interneurons are critical elements in SZ pathophysiology (Coyle, 2004; Homayoun 
and Moghaddam, 2006). For example, recent evidence indicates that changes in 
fast-spiking interneurons are observed blocking the NMDARs (Behrens et al., 
2007) and it has also been observed that mice yielded with several signs of a 
disinhibited cortex after knocking out NMDRs from the calcium-binding protein 
parvalbumin (PV) interneurons (Belforte et al., 2010), usually predominant in the 
basket and chandelier subclasses of interneurons (Figure 2).  
It has also been suggested that chandelier interneurons may be preferentially 
involved in the pathophysiology of SZ (Lewis, 1998). Several of the chandelier 
GABA neurons furnish inhibitory synapses very close to the site action potential 
generation in pyramidal cells. In this way chandelier interneurons are able to 
strongly control the excitatory output of the pyramidal neurons that play a pivotal 
role in working memory and cognitive processes which are altered in SZ 
(Goldman-Rakic, 1995; Lewis and Anderson, 1995). Furthermore, it has been 
hypothesized that dysfunctions in the axon terminals of the chandelier GABA 
neurons could lead to the alterations in GABA neurotransmission observed in SZ 
patients (Lewis, 1998).  
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Figure 2. Schematic representation of some cortical circuit alterations found in SZ 
patients and in animal models of this disorder (Marin, 2012).  
 
 
Finally, recent studies reported an increased expression of GABAA receptor α2 
subunits in SZ patients. It has been suggested that the pre- and postsynaptic 
receptor changes are compensatory responses to deficient GABA release from 
chandelier neurons (Lewis et al., 2005; Gonzalez-Burgos and Lewis, 2008). 
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1.1.1.2. Deficits in neurons projecting to the prefrontal cortex 
It is important to note that inputs from dopaminergic neurons located in the ventral 
mesencephalon (Figure 3) modulate the activity of both pyramidal and GABA 
neurons. Thus it is also possible that dysfunctions in dopaminergic signaling 
contribute to working memory deficits in SZ individuals (Goldman-Rakic et al., 
2004). For example it seems that dopaminergic innervation of the PFC is 
decreased in SZ patients, as indicated by lower levels of expression of tyrosine 
hydroxylase, the rate limiting enzyme in dopamine synthesis and along with a 
reduction in the dopamine transporter (Akil et al., 1999). Furthermore, since it has 
been observed that the inhibition of the dopamine-degrading enzyme catechol-O-
methyl transferase (COMT) significantly increases dopamine levels in rats PFC, 
the availability of extracellular dopamine in the PFC might be reduced in SZ 
(Tunbridge et al., 2004). It is thought that the hypoactivation that occurs in the PFC 
may be followed by a compensatory hyperactivation of directly adjacent regions, 
reproducing a dysfunction in the capacity to engage the functional networks 
subserving executive functions (Barch, 2005; Glahn et al., 2005; Ragland et al., 
2007).  
Specifically, numerous studies have revealed marked dysregulations in PFC 
neurotransmitter systems, involving cholinergic (Mathew et al., 2007; Scarr et al., 
2009), glutamatergic (Bauer et al., 2008; Volk and Lewis, 2010), dopaminergic 
(Guillin et al, 2007) and GABAergic transmission (Volk and Lewis, 2010; 
Gonzalez-Burgos et al., 2010). In addition, there is a longstanding hypothesis 
sustaining that the pathophysiology of SZ is associated to dysfunction of selective 
corticostriatal circuits (Kleist, 1960). Several studies have reported the presence of 
structural abnormalities in the basal ganglia of SZ individuals (Buchsbaum, 1990) 
and also neurochemical imbalances in the corticostriatal circuits (Carlsson and 
Carlsson, 1990).  
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Figure 3. Schematic illustration of functional deficits in PFC circuitry in SZ (Lewis 
and Sweet, 2009). 
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1.2. BASAL GANGLIA 
The basal ganglia are a group of subcortical nuclei, where the major input nucleus 
is represented by the striatum, which is made up of the caudate and putamen. The 
basal ganglia are traditionally involved in the control of the motor movement, but 
also in a variety of associative, cognitive and mnemonic functions (Saint-Cyr et al., 
1995; Graybiel, 1998; Lalonde and Botez-Marquard, 1997; Yin and Knowlton, 
2006; Simpson et al., 2010). The major input to the striatum is derived from the 
cortex, while the globus pallidus, the subthalamic nucleus and the ventral 
tegmental area represent the main output nuclei of the basal ganglia. Furthermore, 
these output structures project to the principal target of the basal ganglia, the 
thalamus. Finally the thalamus, complete a loop involving the cortex, the striatum 
and the thalamus itself, projecting back to the cortex (Figure 4) (Alexander et al., 
1986).  
 
 
 
Figure 4. Simplified picture of the basal ganglia circuitry.  
 
 
On the basis of the classical view of basal ganglia circuitry, it is reported that the 
corticostriatal projections are processed within the striatum and then the 
“transformed signal” is transmitted to the output nuclei of the basal ganglia (Bolam 
et al., 2000). Thus, basal ganglia are primarily involved in action selection, that is, 
the decision of which of several possible behaviors to execute at a given time. 
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Dysfunctions in basal ganglia activity play a central role in a number of 
neurological conditions, including several movement disorders, such as 
Parkinson's and Huntington's diseases. In fact, these two neurodegenerative 
pathologies specifically target the basal ganglia. The most important 
neuropathological alteration in Parkinson's disease is the loss of dopaminergic 
neurons of the substantia nigra (SN), which causes a severe depletion of striatal 
dopamine. At variance, the pathological hallmark of Huntington's disease is a 
massive atrophy of the striatum due to the degeneration of striatal projection 
neurons, striatal interneurons being relatively spared in the disease. 
Studies conducted in humans and non-human primates have demonstrated that 
the striatum plays a crucial role in more complex forms of behaviours, including 
decision making and executive function, in addition to modulating motor control 
and motor learning (Graybiel, 2008). Importantly, it has been shown that lesions 
performed in the dorsomedial striatum influence spatial working memory in the 
same way that lesions of the PFC do (Mair et al., 2002; Voorn et al., 2004). 
Furthermore, the role of the striatum in attentional processes and cognitive control 
has also been suggested in humans. The measure of the attentional set shifting, in 
fact, activates the caudate nucleus in healthy human individuals (Rogers et al., 
2000). So it has been suggested that working memory and other executive 
functions are mediated by both the PFC and striatum, working in concert (Simpson 
et al., 2010).  
Particularly, the striatal subregions are involved in the learning processes through 
at least three distinct circuits:  
 
  a circuit involving associative cortical regions like medial PFC connections 
to the dorsomedial striatum/caudate;  
  sensory and motor cortex circuitry, connected to the dorsolateral 
striatum/putamen; 
  limbic circuitry (i.e. limbic cortex, basolateral amygdala and hippocampus) 
connections to the ventral striatum/nucleus accumbens (Yin and Knowlton, 
2006; Yin et al., 2008). 
 
Several studies with brain damaged patients have reported that, by measuring 
implicit learning using the serial reaction time test, cognitive performance critically 
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depends on the neostriatum function. In fact patients with damage in the medial 
temporal lobe were able to learn, while patients with damage in the basal ganglia 
were cognitively impaired (Knowlton et al., 1994; 1996). 
 
 
1.2.1. Corticostriatal projections and synaptic targets 
It is well known that cortical signals are transmitted within the basal ganglia 
through the direct and indirect pathways (Albin et al., 1989; DeLong, 1990). Briefly, 
in the direct pathway cerebral cortical input to the striatum activates the inhibitory 
projection neurons in the striatum and then the information is transmitted directly 
to the output nuclei. In the indirect pathway the information coming from the cortex 
are then transmitted to the output nuclei via the globus pallidus and the 
subthalamic nucleus (Shink et al., 1996). 
The striatum contains a single class of projections neurons, known as medium 
spiny neurons (MSNs), constituting the 90-95% of the total population of the 
striatal neurons (Kemp and Powell, 1971), utilizing GABA as their main 
neurotransmitter. Furthermore, MSNs receive GABAergic synaptic input from 
striatal cholinergic interneurons, less numerous than MSNs, but able to form 
extensive connections within the striatum (Tepper et al., 2004). 
An equal amount of MSNs belongs to the direct and indirect pathways (Gerfen et 
al., 2004), in which MSNs express dopamine receptors. It is well known that 
striatal dopamine released by nigro-striatal neurons, exerts tonic modulation on 
either MSNs or glutamatergic terminals mainly coming from the motor areas of the 
cerebral cortex and from the thalamus (Cepeda et al., 1993; Flores Hernandez et 
al., 1997; Bamford et al., 2004; Centonze et al., 2004; Yin and Lovinger, 2006). 
The other striatal neurons can be subdivided into three groups: burst-firing 
GABAergic interneurons, also expressing somatostatin, neuropeptide Y and nitric 
oxide; GABAergic interneurons expressing PV and cholinergic interneurons (Dani 
et al., 2007). Several studies have demonstrated that the cortex sends the major 
inputs to PV-positive GABA interneurons (Lapper et al., 1992; Bennett and Bolam, 
1994). 
The activation of corticostriatal neurons is followed by the activation of the 
AMPARs and NMDARs, mainly localized within the synapse (Bernard et al., 1997; 
Kawaguchi, 1997; Bernard and Bolam, 1998), leading then to the neuronal 
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depolarization (Wilson, 1993; Kita, 1996). Noteworthy, several studies reported 
that the PV-positive GABA interneurons receive cortical input and are the principal 
mediators of inhibition in the striatum, providing a feed-forward inhibition of cortical 
information to MSNs. Even though the number of PV-positive GABA interneurons 
is low, they are in a position to strongly control the activity of neurons, giving rise 
to the output of the striatum, by the direct or indirect pathway (Bolam et al., 2000).  
 
 
1.3. KYNURENINE PATHWAY AND NEUROACTIVE KYNURENINES 
The discovery of the endogenous compound KYNA, more than 150 years ago and 
the successive understanding of its biosynthesis and chemical structure led to a 
series of discoveries that turned out to have significant implications for the 
neurosciences. In fact, it was successively demonstrated that KYNA represented 
the first of the "kynurenines", a group of metabolically related compounds derived 
from the essential amino acid tryptophan. Biochemical studies during the first part 
of the 20th century elaborated the enzymatic steps linking the individual members 
of the so-called KP, which was found to account for >90% of peripheral tryptophan 
metabolism in mammals. 
The KP started from tryptophan oxidative ring opening and subsequent 
degradation of the reaction compound. The final product of this metabolic cascade 
(Figure 5) is the NAD+ coenzyme, which plays a crucial role in many fundamental 
biological processes (i.e. redox reactions necessary for mitochondrial function). 
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Figure 5. Tryptophan degradation via KP (Wonodi and Schwarcz, 2010). 
 
 
This catabolic cascade originates the so-called “kynurenines” deriving directly or 
indirectly from L-kynurenine (L-KYN), the major primary degradation product of 
tryptophan. Although the majority of the kynurenines harbor neuroactive 
properties, the triad of KYNA, quinolinic acid (QUIN) and 3-hydroxy-L-kynurenine 
(3-HK) is traditionally referred to as ‘the neuroactive kynurenines’. 
KYNA, one of these metabolites, has long been recognized as a competitive, 
broad-spectrum antagonist of glutamate receptors. At high, non-physiological, 
micromolar concentrations, KYNA inhibits NMDARs, kainate receptors and 
AMPARs (Perkins and Stone, 1982). The action of KYNA on AMPARs has been 
demonstrated to be dual in a dose-dependent manner, evoking facilitation at lower 
concentrations, and exerting neuroinhibition at higher concentrations (µM–mM) 
(Prescott et al., 2006; Rozsa et al., 2008). It has been shown that high 
concentrations of KYNA display anticonvulsant properties and provide an excellent 
protection against excitotoxic injury (Foster et al., 1984).  
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It is well known that at much lower (nM) concentrations than those necessary to 
bind AMPARs, KYNA acts as an antagonist of the glycine allosteric site on the 
NMDAR and as a non-competitive antagonist of the α7 nicotinic acetylcholine 
receptor (α7nAChR) (Hilmas et al., 2001), both of which are critically involved in 
physiological processes underlying learning, memory and other manifestations of 
synaptic plasticity (Hilmas et al., 2001; MacDonald et al., 2006; Albuquerque et al., 
2009). 
In the past few years additional targets of KYNA have been identified, such as the 
former orphan G protein-coupled receptor (Wang et al., 2006) and the aryl 
hydrocarbon receptor, a nuclear receptor able to recognize aromatic hydrocarbons 
and 2,3,7,8-tetrachlorodibezo-p-dioxin (DiNatale et al., 2010). Although it has been 
recently proposed that KYNA is the endogenous ligand for GPR35 (Berlinguer-
Palmini et al., 2013), only the α7nAChR as so far been verified as a “bona fide” 
KYNA receptor in the brain (Hilmas et al., 2001; Grilli et al., 2006; Wu et al., 2010).  
Other studies have also demonstrated antioxidant properties of KYNA, linked to its 
ability to scavenge hydroxyl superoxide anion and other free radicals (Lugo-
Huiltron et al., 2011).  
3-HK, another product of L-KYN degradation and a biological precursor of QUIN is 
present in the brain at nanomolar concentrations and can generate free radicals 
and elevate the oxidative stress levels, causing neuronal damage (Okuda et al., 
1998). Furthermore, it has also been observed after neuronal exposition to both 3-
HK and QUIN a considerable potentiation of excitotoxicity (Guidetti and Schwarcz, 
1999). So far no physiological role of 3-HK in the brain has been established and it 
seems likely that this metabolite does not interact with a specific recognition site 
(Eastman and Guilarte, 1989). 
QUIN possesses excitatory properties due to its capability to directly and 
selectively stimulate NMDARs, as demonstrated by using selective NMDAR 
antagonists. In 1978, Lapin observed convulsions after an intracerebroventricular 
injection of QUIN in mice. This provided the first indication that KP metabolites 
exert central effects (Stone and Perkins, 1981). 
As shown in figure 5, the tryptophan metabolism also includes other metabolites, 
like 3-hydroxyanthranilic acid (3-HANA) and anthranilic acid; however, until now, 
direct effects of these metabolites on neuronal activity (Stone, 1993) have not 
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been demonstrated. Though there are only few examples showing that several 
kynurenines exhibit pro- and anti-oxidant activities in vitro (Giles et al., 2003).  
 
 
1.3.1. Enzymes involved in the kynurenine pathway 
As illustrated in Figure 5, the KP is initiated by the convertion of tryptophan to N-
formylkynurenine by indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-
dioxygenase (TDO). N-formylkynurenine is then degraded to the pivotal metabolite 
kynurenine by formamidase. Several studies have reported that the levels of these 
enzymes in the brain are normally lower than in the peripheral organs. Kynurenine 
undergoes irreversible transamination to form KYNA by four kynurenine 
aminotransferases (KATs). So far it has been established that at least two of these 
enzymes are present in the brain. In the rat brain, KAT I, occurring in a cytosolic 
and mitochondrial form, could have a major function in cortical maturation. This 
enzyme is, in fact, selectively expressed in neurons in the perinatal period (Csillik 
et al., 2002). In the mouse, instead, KAT II is the major enzyme that catalyzes 
KYNA formation (Yu et al., 2004). Nowadays KAT II is thought to be the main 
biosynthetic enzyme of KYNA in the mammalian brain (Guidetti et al., 2007). A 
potent and selective inhibitor of KAT II, (S)-4-ethylsul-fonylbenzoylalanine (ESBA; 
Pellicciari et al., 2006; Figure 6), has been synthetized. 
 
 
 
Figure 6. (S)-4-ethylsul-fonylbenzoylalanine hydrochloride. 
 
 
Biological assays conducted in vitro showed that ESBA inhibits KAT II obtained 
from partially purified rat liver with an IC50 value of 6.1 mM. In vivo studies support 
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these results, demonstrating that the administration of ESBA lowers the 
extracellular levels of KYNA in the rat striatum (Amori et al., 2009). 
A second branch of the KP is characterized by the kynurenine 3-monoxygenase 
(KMO) and kynureninase, responsible for the synthesis of 3-HK and anthranilic 
acid, respectively (Chiarugi et al., 1995). Anthranilic acid is then converted to α-
amino-ω-carboxymuconic acid semialdehyde that under physiologically conditions 
spontaneously rearranges to form QUIN. Finally, QUIN is metabolized to nicotinic 
acid mononucleotide subsequently degraded to the end product NAD+ (Braidy et 
al., 2011).  
 
 
1.3.2. Targets of kynurenic acid 
As previously reported, it is generally assumed that KYNA modifies neuronal 
function because it antagonizes the glycine site of the NMDARs and/or the 
neuronal α7nAChRs. However, whether the basal levels of KYNA found in brain 
extracellular spaces are sufficient to interact with these targets is not fully cleared, 
especially for NMDARs. Another reported target for KYNA is GPR35, an orphan 
receptor negatively coupled to Gi proteins. GPR35 is expressed both in neurons 
and other cells (including glia, macrophages and monocytes). KYNA affinity for 
GPR35 in native systems has not been clarified but current data in modified 
expression systems suggest that it is quite low. However, it has been proposed 
that by interacting with GPR35, KYNA may decrease glutamate release in brain 
and pro-inflammatory cytokines release in cell lines. The inhibition of inflammatory 
mediator release from both glia and macrophages may explain why KYNA has 
analgesic effects in inflammatory models (Moroni et al., 2012). Finally, KYNA has 
been reported as an agonist of aryl hydrocarbon receptor, a nuclear protein 
involved in the regulation of gene transcription and able to cause 
immunosuppression after binding with dioxin. Thus, KYNA has receptors in the 
nervous and the immune systems and may play interesting regulatory roles in cell 
function. However the roles of GPR35 and aryl hydrocarbon receptor in mediating 
endogenous KYNA effects remain to be elaborated. Thus, in the following 
paragraphs the general aspects of α7nAChRs and NMDARs as KYNA molecular 
targets will be briefly described. 
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1.3.2.1. Nicotinic receptor 
Nicotinic acetylcholine receptors (nAChRs) belong to the superfamily of ligand-
gated ion channels and on the basis of their subtypes along with their dendritic, 
somal, axonal, presynaptic and postsynaptic localization, play a different role in 
the central nervous system (CNS). For example, it is well established that 
presynaptically and preterminally located nAChRs increase neurotransmitter 
release, while postsynaptic and non-synaptic nAChRs generally mediate excitation 
(Dani and Bertrand, 2007).  
nAChRs are constituted from five transmembrane subunits, arranged 
symmetrically around a central pore. Each subunit comprises four transmembrane 
domains with both the N- and C-terminus located extracellularly; there are two 
acetylcholine (ACh) binding sites per receptor (Figure 7). 
 
 
Figure 7. A schematic representation of the nAChR structure (Karling, 2002). 
 
 
The structural features of the ligand binding site and the specific amino acid 
interactions establish the pharmacological properties of a specific nAChR subtype 
along with the specific amino acid interactions determining conformational 
transitions (Jensen et al., 2005). 
In addition, there are certain ligands that modulate conformational transitions and 
functions by binding to the subunits or to the interfaces between subunits at 
positions different from the agonist binding site, leading to the phenomena called 
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as allosteric modulation. It is well known that positive modulators potentiate 
nAChRs function, while negative modulators inhibit nAChRs function. Notably, the 
α7nAChRs, one of the well described KYNA target, are good candidate for 
allosteric modulators because of their unique structural organization, low 
sensitivity to acetylcholine and fast kinetics. Among the positive allosteric 
modulators, it is well known that galantamine, physostigmine and codeine, 
effectively increase α7nAChRs activation at subsaturating agonist concentrations 
(Pereira et al., 2002). 
The most studied nicotinic role in CNS regards the modulation of neurotransmitter 
release by presynaptic nAChRs. It is well demonstrated that the activation of 
nAChRs is generally followed by an increase of the release of several 
neurotrasmitters (McGehee and Role, 1995; Albuquerque et al., 1997; Jones et 
al., 1999; Sher et al., 2004). For example, exogenous application of nicotinic 
agonists cause an augmentation in the release of glutamate, GABA and 
acetylcholine, as well as dopamine and serotonin, while nicotinic antagonists often 
diminish the release of these neurotransmitters. Particular functional studies 
revealed that in the rat hippocampus the α7 subunit is at nearly every synapse in 
the CA1 stratum radiatum (Fabian-Fine et al., 2001); in addition, this subunit was 
also found on both glutamatergic and GABAergic presynaptic terminals.  
The nicotine-induced increase of neurotransmitter release is a consequence of the 
presynaptic nAChRs activation that initiates a direct and indirect intracellular 
calcium signal (McGehee and Role, 1995; Wonnacott et al., 1997). Thus, the 
activity of the presynaptic nAChRs increases intraterminal calcium and contributes 
to the increased neurotransmitter release. In addition, nicotinic stimulation, 
increasing glutamate release, promotes synaptic plasticity (Wonnacott et al., 1997; 
Ge and Dani, 2005). 
It has been found that nicotinic receptors are also distributed to preterminal, 
axonal, dendritic and somatic locations (Lena et al., 1993; Zarei et al., 1999). 
 
 
1.3.2.2. Influences of nAChRs on cortical functions: relevance for cognition 
Wide areas of the brain are innervated by diffuse cholinergic afferents. Cholinergic 
innervation to the cortex originates from neurons located within basal forebrain 
nuclei (Wolf, 1991). In addition, a high number of small varicosities that contain 
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synaptic vesicles does not make synaptic contacts with adjacent neurons, thus 
producing volume transmission where acetylcholine and choline reach locations 
distant from the release site (Descarries et al., 1997; Vizi, 2000).  
On the basis of their localizations, nAChRs are supposed to modulate cortical 
activity in a multiple way. For example, it has been observed that activation of 
nAChRs on distal apical dendrites causes a depolarization of the cell and 
promotes action potential firing. On the other hand, if the activation occurs in the 
proximal dendrites nearer to the cell soma, it causes a reduction of the membrane 
impedance and a shunt of the signals incoming from the apical tuft (Dani et al., 
2007). 
It is well known that nAChRs are implicated in a wide range of neuronal diseases 
and mental illnesses (Lena and Changeaux, 1998; Picciotto and Zoli, 2002; Dani 
and Harris, 2005). Several studies have reported that in Alzheimer’s disease, 
Parkinson’s disease and Down syndrome nAChRs are reduced or nicotinic 
mechanisms are impaired, thus contributing to cognitive dysfunctions (Picciotto 
and Zoli, 2002; Perry et al., 2000). Notably, it has to take into account that the 
variable age-related decline of cholinergic transmission and decrease in nAChRs 
numbers influenced the results.  
It has been observed that, generally, nicotinic agonists improve certain forms of 
memory and nicotinic antagonists and/or cholinergic lesions impair memory. It has 
been reported in animal studies that acute or chronic nicotine administration, 
ameliorates working memory. In addition, studies performed in humans using 
nicotinic agonists have demonstrated an improvement in learning and memory 
(Levin et al., 2006). Importantly, the responses to nicotinic agonists are highly 
dose-dependent and those compounds do not have effects at the lowest 
concentration tested (Dani et al., 2007).  
 
 
1.3.2.3. nAChRs and schizophrenia 
Preclinical and clinical studies provided evidence linking SZ to a deficiency of 
α7nAChRs-mediated neurotransmission (Deutsch et al., 2005; Martin and 
Freedman, 2007; Jones et al., 2011). It has been observed that SZ individuals and 
their biological relatives show a deficient gating of P50 auditory event-related 
potential and the locus on chromosome 15, which codes the gene for the 
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α7nAChRs subunit (i.e. CHRNA7) (Freedman et al., 1997). Specifically, P50 
gating alludes to a paradigm in which two acoustic clicks are given about 500 
msec apart, resulting in a reduced P50 response to the second stimulus (Green, 
2006).  
Furthermore, post-mortem studies examining the brains of SZ individuals have 
also reported a reduction of the α7nAChR protein levels in the dentate gyrus and 
CA3 region of the hippocampus along with a degree of global cognitive deficits in 
these individuals (Martin-Ruiz et al., 2003). In addition, recent studies have also 
identified significant connections between brain areas of α7nAChRs expression, 
their impact on other neurotransmitters and how these changes might be linked to 
the dopamine and glutamate theory of SZ.  
Several findings have reported that α7nAChRs are found on midbrain dopamine 
cells bodies of the ventral tegmental area, subthalamic nuclei, presynaptically on 
dopamine terminal regions in the striatum, nucleus accumbens and PFC. 
Moreover α7nAChRs are located on glutamate and GABA neurons that project 
into dopaminergic regions and terminals (Quik et al., 2000; Dani and Bertrand, 
2007; Machaalani et al., 2010). Additionally, dopamine release can be enhanced 
in several brain regions such as the striatum, ventral tegmental area, nucleus 
accumbens and PFC, as a result of the α7nAChR activation (Sydserff et al., 2009; 
Thomsen et al., 2010; Castner et al., 2011). Other studies also reported that 
α7nAChR activation releases GABA from GABAergic interneurons (Albuquerque 
et al., 1998; Frazier et al., 1998) and then GABA, acting on GABAB receptors, 
leads to a reduction of striatal glutamate release that may, in turn, results in the 
increased dopamine release (Bencherif et al., 2012). Moreover, it has recently 
been reported that α7nAChRs modulate glutamate release in the PFC of rats. 
Notably, kynurenine (the precursor of KYNA) and α-bungarotoxin are able to block 
choline-induced stimulation of glutamate release (Kondardsson-Geuken et al., 
2010).  
It has been recognized that interactions between α7nAChRs and NMDARs have 
been implicated in cognitive deficits observed in SZ (Timofeeva and Levin, 2011). 
In a recent paper it has also been hypothesized that interactions between 
α7nAChRs and NMDARs modulate cortical glutamatergic development. In 
addition, an altered α7nAChR-mediated control of synaptic NMDARs, due to the 
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loss of the α7nAChRs, may produce permanent changes contributing to cortical 
impairment present in SZ patients (Lin et al., 2014). 
 
 
1.3.2.4. N-methyl-D-aspartate receptor  
Several studies have shown that hypofunction of the NMDARs has implications in 
the pathophysiology of SZ. NMDARs are heteromeric protein complexes 
constituted of at least one NR1 along with several combinations of the NR2 and/or 
NR3 subunits (Cull-Candy et al., 2001). 
Regarding the activation of the NMDARs, it is well known that magnesium blocks 
the pore of the NMDAR channel, at resting membrane potential. Moreover the 
NMDAR includes a glutamate recognition site on the NR2 subunit and a glycine or 
D-serine modulatory site on the NR1 subunit (Johnson and Ascher, 1987; 
Clements and Westbrook, 1991). In order to activate the NMDAR, it is 
fundamental that the D-serine/glycine site has to be occupied by glutamate (Figure 
8) (Clements and Westbrook, 1991). KYNA acts as an antagonist of the glycine 
allosteric site on the NMDAR. 
 
 
 
Figure 8. Schematic representation of the NMDAR.  
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Notably, NMDAR has the property of being both voltage-dependent and ligand-
gated, giving thus the ability to NMDAR to act as a coincidence detector for 
presynaptic activity and post-synaptic activity. When the NMDAR is activated, the 
calcium influx is permitted through the channel, stimulating intracellular signaling 
cascades that can then influence synaptic plasticity, like long-term potentiation 
(LTP), underlying several types of learning and memory formation (Nicoll, 2003). 
 
 
1.3.2.5. Kynurenic acid, α7nAChRs and NMDARs 
Since endogenous KYNA is able to inhibit both the NMDARs and the α7nAChRs, it 
is reasonable to hypothesize that it might also be involved in cognitive functions. In 
addition, as described above, both of these receptors are known to be critical for 
physiological processes involving synaptic plasticity and more specifically memory 
and learning (MacDonald et al., 2006; Albuquerque et al., 2009). Thus, fluctuations 
in KYNA levels could influence these and related phenomena. Several studies 
reported that increases in brain KYNA levels, induced by the administration of 
kynurenine, lead to cognitive impairments in experimental animals, thus supporting 
this concept (see below). For example, increased KYNA levels disrupt prepulse 
inhibition and auditory sensory gating (Shepard et al., 2003; Erhardt et al., 2004) 
and also cause deficits in contextual learning and memory (Chess and Bucci, 
2006; Chess et al, 2007). Thus, dysfunction of α7nAChRs and NMDARs in SZ 
may be induced or exacerbated by disruptions in the KP. These deleterious effects 
of KYNA are therefore very interesting in view of the fact that SZ patients present 
increased KYNA levels in brain and cerebrospinal fluid (CSF) (Erhardt et al., 2001; 
Schwarcz et al., 2001; Miller et al., 2006; Sathyasaikumar et al., 2011). 
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1.3.3. Kynurenic acid metabolism and regulation in the brain 
In order to provide additional information about the cellular localization of KYNA 
and QUIN in cerebral tissues, several immunocytochemical and lesion studies 
have been performed. The results clearly indicate that glial cells, rather than 
neurons, harbor the enzymatic machinery for the biosynthesis of brain 
kynurenines. Furthermore, all enzymes involved in the KP are primary contained in 
astrocytes and microglial cells (Guidetti et al., 1995; Heyes et al., 1996; Schwarcz 
et al., 1996; Guillemin et al., 2001). In the mammalian brain, the metabolites of the 
KP are normally present in the nanomolar to micromolar concentration range 
(Turski et al., 1988; Baran and Schwarcz, 1990; Smythe et al., 2003). The cerebral 
KP is mainly driven by the pivotal metabolite blood-born kynurenine, which readily 
enters the brain from the circulation (Figure 9) using the large neutral amino acid 
transporter (Fukui et al., 1991). Once in the brain, kynurenine is taken up by 
astrocytes and presumably microglial cells (Speciale and Schwarcz, 1990).  
Notably, KYNA synthesis occurs in the astrocytes, as they do not appear to 
contain kynureninase. Newly produced KYNA is then rapidly released into the 
extracellular milieu where it has access to neuronal α7nAChRs and NMDARs. On 
the contrary, very poor KAT activity is present in the microglial cells and, therefore, 
the QUIN branch of the pathway is favored in these elements (Guillemin et al., 
2001).  
Because of their polar nature and as so far there are no evidence of efficacious 
transport processes, KYNA and QUIN very poorly cross the blood-brain barrier 
(Fukui et al., 1991) and, thus, they must be locally formed within the brain to exert 
their central effects (Schwarcz et al., 2012).  
The intracellular kynurenine concentration determines the enzymatic KYNA 
formation. Furthermore, the release of KNYA is also influenced by several factors. 
For example, it has been demonstrated that KYNA formation, in the presence of 
depolarizing stimuli such as high extracellular K+ concentration, glutamate receptor 
agonists or altered cellular energy metabolism, is reduced and hence extracellular 
KYNA levels. It is noteworthy that in neuron-depleted brain tissue these effects are 
not observed, suggesting that the glial KYNA synthesis in the brain is controlled by 
neuronal activity (Gramsbergen et al., 1997). Some studies have also 
demonstrated that the systemic administration of dopaminergic (Rassoulpour et 
al., 1998) or cholinergic (Hilmas et al., 2001) agents induced extracellular 
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fluctuations in KYNA levels in the brain, but not in the periphery. It has also been 
observed that several of these effects are lost in absence of neurons. Thus KYNA 
production in, and release from, astrocytes depend on neuronal signals 
(Gramsbergen et al., 1997).  
 
 
 
Figure 9. Dynamics of the cerebral kynurenine pathway in the brain (Schwarcz et 
al., 2012).  
 
 
1.3.4. Kynurenic acid and neurotransmission 
As shortly mentioned in the previous paragraphs, it appears that SZ is a 
heterogeneous disease, also characterized by various neurotransmitter 
imbalances. Namely, corticostriatal neuron loops greatly involved in cognitive skills 
are functionally impaired. Thus, it becomes relevant that the reported disruption of 
the KP of tryptophan degradation, in particular the alterations in KYNA levels may 
cause an exacerbation of the neurotransmitter specific dysregulations observed in 
SZ (Erhardt et al., 2001; Schwarcz et al., 2001 Miller et al., 2006; Wonodi et al., 
2011). For example, it has been demonstrated that extracellular dopamine levels 
in rat striatum are decreased after intrastriatal infusion of nanomolar 
concentrations of KYNA. This effect is mediated by α7nAChRs located on the 
glutamatergic nerve terminals, rather than the NMDARs, since the local perfusion 
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of KYNA in combination with choline, the selective α7nAChRs agonist, resulted in 
a prevention of the decrease in extracellular levels of dopamine induced by KYNA 
(Rassoulpour et al., 2005). In addition, the same study revealed that after 
treatment with a non-specific astrocyte poisoning leading to an interference with 
KYNA synthesis, extracellular dopamine levels in the striatum were increased. 
Thus, dopaminergic tone is regulated by the fluctuations in the astrocytic 
production of KYNA. Similarly, KYNA induce a reduction in striatal glutamate, first 
targeting α7nAChRs on glutamatergic nerve terminals. In addition, these results 
are in line with other studies showing that low concentrations of galantamine, a 
positive allosteric modulator of α7nAChRs (Santos et al., 2002; Samochocki et al., 
2003), prevent the KYNA-induced reduction of extracellular dopamine levels, in 
the same way of the choline, the direct α7nAChRs agonist (Rassoulpour et al., 
2005).  
As cognitive deficits affecting SZ individuals involve several central areas, the 
effects of KYNA have also been evaluated in other brain regions such as PFC and 
hippocampus. It has been shown that KYNA at nanomolar concentrations induced 
a reduction in the extracellular glutamate levels, not only in the striatum, but also in 
the rat PFC (Carpenedo et al., 2001; Rassoulpour et al., 2005; Grilli et al., 2006; 
Wu et al., 2007, 2008). On the other hand, reductions in the endogenous KYNA 
synthesis induced an increase in the extracellular levels of glutamate (Wu et al., 
2006; 2008) suggesting that KYNA bi-directionally modulate glutamatergic 
transmission by endogenously formed KYNA. In addition, other studies reported 
that endogenous KYNA is also able to modulate basal levels of PFC acetylcholine 
in the rat cortex. Notably, the perfusion of ESBA (Pellicciari et al., 2006), the 
selective inhibitor of the astrocyte enzyme KAT II which catalyses the KYNA 
formation from its bioprecursor L-KYN, reduced cortical KYNA levels and 
increased cortical acetylcholine levels (Zmarowski et al., 2009). Furthermore, the 
functional effects of nanomolar KYNA concentrations can be replicated by specific 
α7nAChR ligands (i.e. methylcaconitine, α-bungarotoxin) (Rassoulpour et al., 
2005; Lopes et al., 2007). On the contrary, these effects are not observed using 
selective antagonist of the glycineB site of the NMDARs (Hilmas et al., 2001).  
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1.3.5. Possible relevance of astrocyte-derived kynurenic acid 
Since astrocytes are responsible for the de novo synthesis of KYNA from L-
kynurenine in the brain, these cells deserve consideration as modulators of 
α7nAChRs function and consequently also cholinergic transmission (Zmarowski et 
al., 2009).  
For much of the past century, astrocytes were considered just as a subtype of glial 
cell that contacts synapses and the vasculature, providing metabolic support to the 
neurons. Recent experimental evidence suggests that in addition to being 
essential supporters of neuronal function, astrocytes also closely interact with 
neurons and participate in the regulation of synaptic neurotransmission. It has 
been proposed that synapses are tripartite, where the astrocytic process is 
associated with the presynaptic and postsynaptic elements of the synapses. In 
addition, it has also been demonstrated that astrocytes possess a large array of 
neurotransmitter receptors (Araque et al., 1999; Halassa et al., 2007) and they can 
also release chemical transmitters such as, among others, glutamate, GABA and 
glycine. In addition, impairments of the bi-directional communication between 
astrocytes and neurons, lead to an abnormal neurotransmission and information 
processing. Thus, it has been hypothesized that the astrocytes could also be 
involved in various manifestations of brain dysfunctions (Kettenmann and 
Ransom, 2004; Tian et al., 2005). Importantly, astrocytes may also regulate 
synaptic communication through volume transmission, the diffusion through the 
brain extracellular fluid of neurotransmitters released at points that may be remote 
from the target cells with the resulting activation of extrasynaptic receptors (Agnati 
and Fuxe, 2000).  
Biochemical and immunocytochemical studies, demonstrated that astrocytes are 
the major source of KYNA in the mammalian brain (Ceresoli-Borroni, et al., 1999; 
Rejdak et al., 2003; Melendez-Ferro et al., 2005). Thus, in the brain, changes in 
extracellular KYNA concentrations reflect similar fluctuations in intracellular KYNA 
formation, determined by intra-astrocytic control mechanisms (Schwarcz and 
Pellicciari, 2002). These regulatory events are likely to influence the 
neuromodulatory effects of astrocyte-derived KYNA in the normal and diseased 
human brain. For example, it has been reported that fluctuations in the astrocytic 
production of KYNA, through indirect local actions possibly involving volume 
transmission, inversely regulate striatal dopaminergic tone. Such a mechanism 
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may profoundly influence dopamine function under physiological and pathological 
conditions (Wu et al., 2007). From a pathological point of view, it has been 
proposed (see above) that astrocytes lack kynurenine-hydroxylase so that large 
amounts of kynurenine KYNA are produced, while minor amounts of QUIN are 
normally synthesised. This suggests that astrocytes alone are neuroprotective by 
minimising QUIN production and maximising synthesis of KYNA. However, 
kynurenine added to macrophages led to significant production of QUIN. Thus, in 
the presence of macrophages and/or microglia, astrocytes could be neurotoxic by 
producing large concentrations of kynurenine that can be metabolised by 
neighbouring monocytic cells to QUIN (Guillemin et al., 2001). 
 
 
1.3.6. Kynurenine pathway and brain dysfunctions  
Kynurenines have become recognized as key players in the mechanism leading to 
neuronal damage, neurodegenerative pathologies and neuroimmunological 
disorders (Table 1). As already reported, a link between endogenous kynurenines 
and excitotoxic phenomena has been suggested (Vecsei et al., 2012). In addition, 
it is now generally accepted that a dysfunction of the KP metabolism may have 
untoward effects on brain functions (Schwarcz et al., 2012). However, the exact 
nature of the cellular and molecular events underlying these effects is not yet 
definitively established. Among other hypotheses, it has been proposed that some 
pathologies of the CNS could be due to an imbalance of KYNA, QUIN and 3-HK 
alone or in concert (Schwarcz and Pellicciari, 2002; Schwarcz et al., 2012; 
Szalardy et al., 2012; Vecsei et al., 2012). Furthermore, several experimental 
animal studies have also investigated the possible secondary role of the KP, as 
mediator of central dysfunctional states. Thus, it has been demonstrated that in 
presence of pathogenic events, kynurenine brain levels are often abnormal (Stone, 
2002).  
  
28 
 
 
 
Table 1. Correlation between neuroactive kynurenines and central nervous system 
pathologies (Schwarcz and Pellicciari, 2002).  
 
 
For example, it has been observed that substantial elevations of 3-HK and QUIN 
levels occur in response to the activation of glial cells or when macrophages 
infiltrate the brain during immunological compromises. Since the KAT activity is 
very low in microglia, the increases in 3-HK and QUIN come with relatively modest 
changes in KYNA formation. Furthermore, has not so far been consistently seen a 
reduction in the brain levels of neuroactive kynurenines after injurious events. This 
could be explained by the fact that if localized neuroactive kynurenine level 
reductions take place, they are probably obscured by the upregulation of 
kynurenine synthesis in reactive glial cells (Schwarcz and Pellicciari, 2001).  
It is noteworthy that the fundamental basis of the KP metabolism characterized in 
rodents and other mammals might be also applied to humans. Numerous post-
mortem studies have investigated about the disposition of kynurenines in the 
human brain along with analysis in serum and CSF. These studies revealed that 
almost always diseases affecting the human brain shown KP-related changes that 
parallel those seen in relevant animal models (Stone, 2001).  
However, not all disease-linked changes in cerebral kynurenine metabolism in 
humans can be easily associated to animal studies. For example, so far, it is not 
clear why in the end-stage of Huntington’s disease KYNA levels are markedly 
reduced (Beal et al., 1990) or why in SZ KYNA levels are elevated in the cortex 
(Schwarcz et al., 2001).  
29 
 
1.3.7. Kynurenic acid and schizophrenia 
Clinical studies have reported that KYNA concentrations were significantly 
increased in PFC and CSF of SZ patients (Erhardt et al., 2001; Schwarcz et al., 
2001). Furthermore, it has also been demonstrated that the upregulation of KYNA 
levels in SZ was associated with elevations in the tissue levels of L-kynurenine, 
the KYNA’s immediate bioprecursor (Figure 8) (Schwarcz et al., 2001).  
It was originally thought that the high levels of L-kynurenine seen in SZ patients 
could be a direct consequence of its increased synthesis catalyzed by either TDO 
or IDO, based on the evidence that both of them are dysregulated in inflammatory 
and immune sensitization events. However, recent studies have demonstrated that 
even though the expression of TDO gene is significantly increased in SZ patients, 
these dysregulations seem to be exacerbated in individuals with additional risk 
genes. Furthermore, brain IDO gene expression seems to be normal in individuals 
affected by SZ. Thus, more recently a different mechanism possibly involved in the 
observed increased KYNA levels in SZ patients has been proposed. In particular, 
it has been suggested that a reduction in KMO activity in the periphery and/or in 
the brain of SZ subjects could lead to abnormally high cortical concentrations of L-
kynurenine and, subsequently, to high KYNA levels. In fact, KMO, the enzyme 
converting L-kynurenine to 3-HK, shows much higher activity in peripheral tissues 
than in the brain. Thus, it seems likely that under certain physiological conditions 
or during pathological events, an increase of L-kynurenine levels might overstep 
the catabolic capacity of KMO, thus leading to brain KYNA formation (Figure 10; 
Wonodi and Schwarcz, 2010). 
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Figure 10. Kynurenine pathway in schizophrenia (Wonodi and Schwarcz, 2010). 
 
 
The high concentrations of brain KYNA levels in the PFC of SZ individuals, may be 
clinically relevant since it is well established that hypofunction of both NMDAR and 
the α7nAChR are implicated in SZ pathophysiology and, in particular, in the 
cognitive deficits associated with the disease.  
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2. AIM 
 
Dysregulations of the KP pathway of tryptophan degradation, causing hyper- or 
hypofunction of active metabolites, have been associated with several CNS 
disorders, as widely described in the Introduction. In particular KYNA, a 
neuroactive metabolite of the KP, has received in the last decades considerable 
attention from neurobiologists and neuroscientists. The reasons of this interest 
derive from the observations that even relatively low fluctuations in brain KYNA 
levels have pronounced consequences, influencing neurotransmission and 
affecting cognitive and motor behaviors in experimental animals (Schwarcz et al., 
2012). Consciousness of these bi-directional effects has led to the hypothesis that 
endogenous KYNA is a significant neuromodulator in the mammalian brain. 
Notably, this role likely extends to pathological situations, which frequently present 
with significant changes in brain KYNA levels. Examples include catastrophic 
neurodegenerative disorders (e.g. Huntington’s disease and Alzheimer’s disease) 
as well as psychiatric diseases (e.g. SZ) (Schwarcz et al., 2012; Szalardy et al., 
2012). Therefore, understanding the nature and characteristics of the remarkable 
neuromodulatory properties of KYNA have implications for brain physiology and 
pathology alike.  
Previous studies demonstrated that increased KYNA concentrations reduce 
extracellular dopamine and glutamate levels in distinct brain regions such as the 
striatum, the PFC and the hippocampus (Carpenedo et al., 2001; Rassoulpour et 
al., 2005; Grilli et al., 2006; Wu et al., 2010; Banerjee et al., 2012) and these 
effects have been associated to KYNA-induced neuroprotection or CNS 
dysfunctions. On the contrary, no studies previously investigated the possibility 
that endogenous KYNA might also influence the in vivo levels of GABA, the major 
inhibitory neurotransmitter in the mammalian brain. As such an effect may have 
significant physiological consequences and may also have implications for 
pathological events, in the present study we acutely manipulated KYNA levels and 
assessed extracellular GABA concentrations over time through microdialysis 
studies in the striatum and the PFC of awake, freely moving rats. These two brain 
regions were chosen because they play essential roles in cognitive processes and 
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the striatum is also involved in various neuropathological disturbances, such as 
Huntington’s and Parkinson’s diseases in which dysfunctions in KP have been 
largely documented. Finally, as a previous electrophysiology study demonstrated 
that α7nAChR-dependent glutamatergic transmission is more sensitive to KYNA 
than α7nAChR-dependent-GABAergic signaling in hippocampal cell cultures 
(Banerjee et al., 2012; Albuquerque and Schwarcz, 2013), the present research 
included parallel determinations of extracellular GABA and glutamate levels both 
in the rat striatum and PFC.  
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3. MATERIAL AND METHODS 
 
3.1. MICRODIALYSIS 
Cerebral microdialysis is a well-established laboratory tool which permits the 
monitoring of neurotransmitters and other biological molecules from interstitial 
fluids. This method is widely used for sampling and quantifying neurotransmitters, 
neuropeptides, and hormones in the brain and periphery. Depending on the 
availability of an appropriate analytical assay, virtually any soluble molecule in the 
interstitial space fluid can be measured by microdialysis. In addition, microdialysis 
is being increasingly used as a bedside monitor to provide on-line analysis of brain 
tissue biochemistry during neurointensive care. 
The microdialysis concept is based on the biological tissue implantation of a 
catheter consisting of a fine double lumen probe, lined at its tip with a semi-
permeable dialysis membrane. The probe is then perfused via an inlet tube with 
fluid isotonic to the tissue interstitium. The perfusate passes along the membrane 
before exiting via outlet tubing into a collecting chamber (Figure 11). Diffusion 
drives the passage of molecules across the membrane along their concentration 
gradient. Molecules at high concentration in the brain extracellular fluid pass into 
the perfusate with minimum passage of water and, as the perfusate flows and is 
removed at a constant rate, the concentration gradient is maintained. It is usually 
state that the microdialysis probe therefore acts an artificial blood capillary and the 
concentration of substrate in the collected fluid (microdialysate) will depend in part 
on the balance between substrate delivery to, and uptake/excretion from, the 
extracellular fluid (Figure 11). This simple concept provides a powerful technique 
with many potential applications in which any molecule small enough to pass 
across the membrane can be sampled.  
Microdialysis is also commonly used for the continuous and local administration of 
exogenous compounds (reverse microdialysis). In this case, the compound of 
interest is dissolved into the perfusion medium. 
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Figure 11. Schematic picture illustrating the principle of microdialysis sampling. 
 
 
As previously reported, microdialysis probes are constituted of a length of tubular 
dialysis membrane through which a solution is constantly perfused. The dialysis 
membrane is semipermeable and permits free transport of some but not all 
solutes. Permeability is typically limited to compounds with molecular masses 
˂20,000 Da. A variety of membranes are available which differ in pore size and 
material used. The length of the membrane is chosen based on the dimension of 
the brain area under examination. In this study we used 2 mm membrane length 
probes.  
It has been clearly demonstrated that the concentration of a given molecule in the 
dialysate will be lower than its real concentration in the brain extracellular fluid 
unless there is total equilibration across the dialysis membrane. The proportion of 
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the true concentration collected in the dialysate is termed the relative recovery and 
is dependent on membrane pore size, membrane area, rate of flow of perfusate 
and diffusion speed of the substance. 
In vivo microdialysis is not without limitations. While suitable for the real-time 
measurement of endogenous substances, animal studies have shown that 
prolonged probe placement results in edema in the surrounding region and 
infiltration of the membrane by inflammatory cells, rendering the results obtained in 
such a situation unreliable. This problem has been surmounted in the closed 
technique in which the modification of the probe is such that it is inserted into a 
relatively superficial “bolt” which may be locked upon removal of the probe. This 
technique of repeated probe insertion has been employed in animal studies and 
has not been shown to be associated with any increase in gliosis in the region of 
probe placement. Thus, the aspect of this technique that ensures minimal trauma 
to the cerebral parenchyma may be preserved along with the benefit of 
continuous, serial sampling. Another proposed benefit to the technique of 
intermittent sampling as opposed to the use of a continuous indwelling probe is the 
decreased risk of infection. 
 
 
3.2. ANIMALS 
Adult male Sprague-Dawley rats (225-250 g, Harlan Italy S.r.l., Udine, Italy) were 
used. The animals, housed in cages in groups of five animals in a temperature- 
and relative humidity- controlled environment with a regular 12 hour light/dark 
cycle, had free access to food and water. Following delivery, the animals were 
allowed to adapt to the environment for at least one week before the experiment 
commenced. 
Experiments were carried out in strict accordance with the European Communities 
Council Directive (86/609/EEC) and the Guidelines released by the Italian Ministry 
of Health (D.L. 116/92) and (D.L. 111/94-B). A formal approval to conduct the 
experiments described was obtained by the local Ethics Committee (University of 
Ferrara, Italy). Efforts were made to minimize the number of animals used and to 
reduce pain and discomfort. The ARRIVE guidelines for reporting research 
(http://www.nc3rs.org.uk/ARRIVE) were followed throughout the design and 
execution stage of all experiments. 
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3.3. MICRODIALYSIS EXPERIMENTS 
 
3.3.1. Surgery 
On the day of surgery, the animals, kept under isoflurane anaesthesia (1.5% 
mixture of isoflurane and air), were mounted in a David Kopf stereotaxic frame 
(Tujunga, CA, USA) with the upper incisor bar set at -2.5 mm below the interaural 
line. After exposing the skull and drilling a burr hole, a guide cannula (CMA12; 
CMA Microdialysis, Solna, Sweden) was positioned on top of the striatum 
(stereotaxic coordinates = AP: 1 mm anterior to bregma, L: 2.5 mm from the 
midline, V: 3.5 mm below the dura) or in the medial PFC (AP: 3.2 mm anterior to 
bregma, L: 0.6 mm from the midline; V:2.0 mm below the dura; Paxinos & Watson, 
1986) and secured to the skull with anchor screws and acrylic dental cement. After 
surgery, the animals were housed individually in microdialysis chambers. 
 
 
3.3.2. Experimental protocol 
On the day after surgery, a microdialysis probe of concentric design (CMA12; 
molecular weight cutoff: 20 kD; outer diameter 0.5 mm; length of dialysing 
membrane 2 mm; Alfatech S.p.A., Genova, Italy) was inserted through the guide 
cannula, extending throughout the striatum or the PFC. The probe was connected 
to a microperfusion pump (CMA 100; Carnegie Medicin, Stockholm, Sweden) set 
to a speed of 1 µl/min and perfused with Ringer solution containing (in mM): NaCl, 
144; KCl, 4.8; MgSO4, 1.2; CaCl2, 1.7; pH 6.7 (Figure 12). The probe was 
employed both for intrastriatal or intracortical perfusion with the selected 
compounds and the recovery of perfusate samples for measurement of local 
glutamate and GABA levels. Perfusates were collected every 30 min. After three 
stable basal glutamate and GABA values were obtained, KYNA (30-1000 nM), 
galantamine (5 µM), ESBA (1 mM, 5 mM) 7-Cl-KYNA (100 nM) and/or CNQX (100 
µM) were locally perfused for 2 h (four samples). Subsequently, perfusion with 
Ringer solution continued for another 2.5 h (5 samples). In some experiments 
performed in the striatum, tetrodotoxin (TTX; 2 µM) was locally perfused 3.5 h prior 
to the addition of KYNA, and perfusion continued until the end of the experiment. 
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Following each experiment, the brain was removed from the skull, and the position 
of the dialysis probe was verified using 30 µm-thick coronal cryostat sections. Only 
those animals in which the probe was correctly located were included in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Schematic representation of the experimental protocol. In 1 is 
illustrated the microinfusion pump that is connected to a syringe selector as shown 
in 2, perfusing in the probe represented by 3. In 4 is illustrated a swivel, to permit a 
free movement of the animal and 5 represent the fractional collector.  
 
 
3.3.3. Glutamate and GABA analysis 
Glutamate and GABA levels in the dialysate were measured by HPLC coupled to 
fluorimetric detection. Briefly, 25 μl samples were pipetted into glass microvials 
and placed in a temperature-controlled (4°C) Triathlon autosampler (Spark 
Holland, Emmen, The Netherlands). Thirty μl of o-
phthaldialdehyde/mercaptoethanol reagent were added to each sample, and 30 μl 
of the mixture were injected onto a Chromsep analytical column (3 mm inner 
diameter, 10 cm length; Chrompack, Middelburg, The Netherlands).  The column 
was eluted at a flow rate of 0.48 ml/min (Beckman125 pump; Beckman 
Instruments, Fullerton, CA, USA) with a mobile phase containing 0.1 M sodium 
acetate, 10% methanol and 2.2% tetrahydrofuran (pH 6.5). Glutamate and GABA 
were detected by means of a Jasco fluorescence spectrophotometer FP-2020 
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Plus (Jasco, Tokyo, Japan).  The retention times of glutamate and GABA were 
~3.5 and ~ 15.0 min, respectively.  
 
 
3.4. MATERIALS 
KYNA, 7-Cl-KYNA, CNQX, TTX and galantamine were obtained from Sigma 
Chemical Co. (St. Louis, MO, USA). For administration by reverse microdialysis, 
KYNA, 7-Cl-KYNA, CNQX, and galantamine were dissolved in Ringer solution and 
delivered through the probe. TTX was dissolved in water at a concentration of 1 
mM and stored at -80°C. Upon thawing, the toxin was diluted in Ringer solution on 
the day of the experiment. ESBA, kindly provided by R. Pellicciari (University of 
Perugia, Italy), was synthesized and used in microdialysis experiments as 
described (Pellicciari et al., 2006). All other chemicals were of the highest 
commercially available purity. 
 
 
3.4.1. Data management and statistical analysis 
Data were not adjusted for recovery from the microdialysis probe. Results from 
individual time points are reported as percentages of the mean of the last three 
baseline samples before treatment commenced. For experiments involving KYNA 
and TTX, results from individual time points are reported as percentages of the 
mean of the three samples prior to KYNA perfusion. Data are expressed as the 
mean ± SEM, and only the statistical significance of the peak effects (maximal 
responses) is shown in the Figures. In addition, the area created by the curve 
(AUC), reflecting the duration of the effect, was determined for each animal. Area 
values (overall effects) were calculated as percentages of changes in baseline 
value over time by using the trapezoidal rule. Statistical analysis was carried out 
by analysis of variance (ANOVA) followed by the Newman-Keuls test for multiple 
comparisons.  
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4. RESULTS 
4.1. STRIATUM 
 
4.1.1. Basal extracellular GABA and glutamate levels 
Basal extracellular GABA and glutamate levels, measured in 30 min dialysate 
fractions, were 19.4 ± 0.8 nM and 327 ± 18 nM (n = 23), respectively.  
In control rats, these levels remained essentially stable over the duration of the 
experiment (6 h), with a fluctuation of no more than 5-6%.  
 
 
4.1.2. Effects of intrastriatal KYNA perfusion 
Local perfusion with KYNA (30-1000 nM) caused concentration-dependent 
decreases in extracellular GABA levels (Figure 13A). This reduction was already 
seen in the first sample after the introduction of KYNA, and GABA levels gradually 
returned to baseline values after KYNA was removed from the perfusion solution. 
A statistically significant effect was obtained with 100 nM KYNA, and relatively 
small further reductions were seen after perfusion with higher concentrations of 
KYNA (Figure 13A; maximal decrease to 57 ± 4 % of control values at 1000 nM 
KYNA). Statistical assessment of the AUC revealed that the effects of 300 nM and 
1000 nM KYNA exceeded the effects of 100 nM KYNA (Figure 13B). 
As shown in Figure 14, local perfusion with KYNA also caused a concentration-
dependent reduction in extracellular glutamate levels. A statistically significant 
effect was obtained with 100 nM KYNA, and relatively small further reductions 
were seen after perfusion with higher concentrations of KYNA (Figure 14; maximal 
decrease to 57 ± 8 % of control values at 300 nM KYNA). Statistical assessment 
of the AUC revealed that the effects of 300 nM and 1000 nM KYNA exceeded the 
effects of 100 nM KYNA (Figure 14B). 
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Figure 13. Effect of kynurenic acid (KYNA) on extracellular GABA levels in the rat 
striatum. KYNA was applied for 2 h by reverse microdialysis (bar). See text for 
absolute levels of extracellular GABA. A: data (means ± SEM; n = 6 per group) are 
expressed as a percentage of the averaged three baseline values prior to 
treatment. B: bargraphs of the areas under the curves, calculated as the 
percentage of change in basal values over time. Data were analyzed by two-way 
(A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple 
comparisons. *P<0.05, **P<0.01 compared to both controls and 30 nM KYNA; 
°P<0.05 compared to the effects of 100 nM KYNA. 
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Figure 14 Effect of kynurenic acid (KYNA) on extracellular glutamate levels in the 
rat striatum. KYNA was applied for 2 h by reverse microdialysis (bar). See text for 
absolute levels of extracellular glutamate. A: data (means ± SEM; n = 6 per group) 
are expressed as a percentage of the averaged three baseline values prior to 
treatment. B: bargraphs of the areas under the curves, calculated as the 
percentage of change in basal values over time. Data were analyzed by two-way 
(A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple 
comparisons. *P<0.05, **P<0.01 compared to both controls and 30 nM KYNA; 
°P<0.05 compared to the effects of 100 nM KYNA. 
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4.1.3. Effects of intrastriatal 7-Cl-KYNA perfusion 
Intrastriatal perfusion of 7-Cl-KYNA (100 nM), a NMDAR antagonist acting at the 
glycineB site, did not affect extracellular GABA and glutamate levels. Moreover, co-
perfusion with 7-Cl-KYNA (100 nM) did not influence the reduction in extracellular 
GABA and glutamate levels caused by 100 nM KYNA (Figure 15 and 16). 
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Figure 15. Effect of 100 nM 7-chlorokynurenic acid (7-Cl-KYNA), perfused alone 
or in combination with 100 nM KYNA, on extracellular GABA levels in the rat 
striatum. Test agents were applied for 2 h by reverse dialysis (bar). A: data 
(means ± SEM) are expressed as a percentage of the averaged three baseline 
values prior to treatment. B: bargraphs of the areas under the curves, calculated 
as the percentage of changes in basal values over time. Data were analyzed by 
two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for 
multiple comparisons. **P<0.01 compared to both controls and 7-Cl-KYNA alone. 
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Figure 16. Effect of 100 nM 7-chlorokynurenic acid (7-Cl-KYNA), perfused alone 
or in combination with 100 nM KYNA, on extracellular glutamate levels in the rat 
striatum. Test agents were applied for 2 h by reverse dialysis (bar). A: data 
(means SEM) are expressed as a percentage of the averaged three baseline 
values prior to treatment.  B: bargraphs of the areas under the curves, calculated 
as the percentage of changes in basal values over time. Data were analyzed by 
two-way (A) or one-way (B) ANOVA and subsequent Newman-Keuls test for 
multiple comparisons. **P<0.01 compared to both controls and 7-Cl-KYNA alone. 
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4.1.4. Effects of intrastriatal galantamine perfusion 
Intrastriatal perfusion of galantamine (5 µM) moderately, but significantly, 
increased local extracellular GABA and glutamate levels. These effects were 
transient, and the aminoacid concentrations promptly reverted to baseline values 
following the removal of galantamine from the perfusion solution. When 
galantamine (5 µM) and KYNA (100 nM) were co-infused, extracellular GABA and 
glutamate levels remained unchanged compared to the respective baseline values 
(Figure 17 and Figure 18).  
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Figure 17. Effects of 5 μM galantamine, perfused alone or in combination with 100 
nM KYNA, on extracellular GABA levels in the rat striatum. Test agents were 
applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed as 
a percentage of the averaged three baseline values prior to treatment. B: 
bargraphs of the areas under the curves, calculated as the percentage of changes 
in basal values over time. Data were analyzed by two-way (A) or one-way (B) 
ANOVA and subsequent Newman-Keuls test for multiple comparisons. *P<0.05 
compared to both controls and galantamine + KYNA. 
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Figure 18. Effects of 5 μM galantamine, perfused alone or in combination with 100 
nM KYNA, on extracellular glutamate levels in the rat striatum. Test agents were 
applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed as 
a percentage of the averaged three baseline values prior to treatment. B: 
bargraphs of the areas under the curves, calculated as the percentage of changes 
in basal values over time. Data were analyzed by two-way (A) or one-way (B) 
ANOVA and subsequent Newman-Keuls test for multiple comparisons. *P<0.05 
compared to both controls and galantamine + KYNA. 
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4.1.5. Effects of intrastriatal ESBA perfusion  
Intrastriatal perfusion of ESBA (1 mM), a specific inhibitor of KYNA's biosynthetic 
enzyme KAT II (Pellicciari et al., 2006), reduces the extracellular concentration of 
KYNA, reaching a nadir of 68% of baseline values after 1.5 h (Amori et al., 2009). 
In the present experiments, this treatment increased extracellular GABA levels, 
reaching a peak value of 156 ± 6% of baseline after 1 h (Figure 19). GABA levels 
gradually returned to control values after ESBA was removed from the perfusion 
solution. Co-application of KYNA (100 nM) completely abolished the effect of 
ESBA (1 mM) on extracellular GABA levels (Figure 19). 
Intrastriatal perfusion of ESBA (1 mM) also increased extracellular glutamate 
levels, and this effect, too, was neutralized by co-perfusion of KYNA (100 nM; 
Figure 20). 
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Figure 19. Effect of 1 mM (S)-4-(ethylsulfonyl)benzoylalanine (ESBA), perfused 
alone or in combination with 100 nM KYNA, on extracellular GABA levels in the rat 
striatum. Test agents were applied for 2 h by reverse dialysis (bar). A: data 
(means ± SEM) are expressed are expressed as a percentage of the averaged 
three baseline values prior to treatment. B: bargraphs of the areas under the 
curves, calculated as the percentage of changes in basal values over time. Data 
were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-
Keuls test for multiple comparisons. **P<0.01 compared to both controls and 
(ESBA + KYNA). 
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Figure 20. Effect of 1 mM (S)-4-(ethylsulfonyl)benzoylalanine (ESBA), perfused 
alone or in combination with 100 nM KYNA, on extracellular glutamate levels in the 
rat striatum. Test agents were applied for 2 h by reverse dialysis (bar). A: data 
(means ± SEM) are expressed are expressed as a percentage of the averaged 
three baseline values prior to treatment. B: bargraphs of the areas under the 
curves, calculated as the percentage of changes in basal values over time. Data 
were analyzed by two-way (A) or one-way (B) ANOVA and subsequent Newman-
Keuls test for multiple comparisons. **P<0.01 compared to both controls and 
(ESBA + KYNA). 
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4.1.6. Effects of intrastriatal perfusion with TTX in combination with ESBA 
As shown in Figure 21 and 22, when TTX (2 μM) was included into the perfusion 
medium 2 h before the onset of the collection period till the end of the experiment, 
it significantly but partially (p<0.05) counteracted the ESBA (1 mM)-induced 
increase in both extracellular GABA and glutamate levels. 
By itself TTX induced a slight reduction in both extracellular GABA and glutamate 
levels. These effects were significant (P<0.05) by evaluating the areas under the 
curves, but not the time point effects (Figure 23 and 24). 
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Figure 21. Effect of tetrodotoxin (TTX) perfusion on (S)-4-
(ethylsulfonyl)benzoylalanine (ESBA; 1 mM)-induced increase in extracellular 
GABA levels in the rat striatum. TTX (2 μM) was included into the perfusion 
medium 2 h before the onset of the collection period till the end of the experiment 
(open bar), while ESBA was applied for 2 h by reverse dialysis (black bar). A: data 
(means SEM) are expressed as a percentage of the averaged three baseline 
values prior to treatment. B: bargraphs of the areas under the curves, calculated 
as the percentage of changes in basal values over time. Data were analyzed by 
Student’s t-test. *P<0.05 compared to controls. 
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Figure 22. Effect of tetrodotoxin (TTX) perfusion on (S)-4-
(ethylsulfonyl)benzoylalanine (ESBA; 1 mM)-induced increase in extracellular 
glutamate levels in the rat striatum. TTX (2 μM) was included into the perfusion 
medium 2 h before the onset of the collection period till the end of the experiment 
(open bar), while ESBA was applied for 2 h by reverse dialysis (black bar). A: data 
(means SEM) are expressed as a percentage of the averaged three baseline 
values prior to treatment. B: bargraphs of the areas under the curves, calculated 
as the percentage of changes in basal values over time. Data were analyzed by 
Student’s t-test. Data were analyzed by Student’s t-test. *P<0.05 compared to 
controls. 
 
-2 -1 0 1 2 3 4 5 6
0
10
Time (h)
E
x
tr
a
c
e
ll
u
la
r
 g
lu
ta
m
a
te
 l
e
v
e
ls
 (
%
 o
f 
b
a
sa
l 
v
a
lu
e
s)
ESBA (1 mM)
CONTROL
40
60
80
100
120
140
160
180
TTX (2 M)
ESBA
-1000
0
1000
2000
3000
4000
5000
6000
7000
8000
CONTROL
ESBA (1 mM)
*
A
r
e
a
 u
n
d
e
r
 t
h
e
 c
u
r
v
e
 (

 b
a
sa
l 
%
 x
 t
im
e
)
A
B
54 
 
 
Figure 23. Effect of tetrodotoxin (TTX) on extracellular GABA levels in the rat 
striatum. TTX was applied for 4.5 h by reverse microdialysis (bar). See text for 
absolute levels of extracellular GABA. A: data (means ± SEM; n = 5 per group) are 
expressed as a percentage of the averaged three baseline values prior to 
treatment. B: bargraphs of the areas under the curves, calculated as the 
percentage of change in basal values over time. Data were analyzed by two-way 
(A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple 
comparisons. *P<0.05, compared to controls. 
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Figure 24. Effect of tetrodotoxin (TTX) on extracellular glutamate levels in the rat 
striatum. TTX was applied for 4.5 h by reverse microdialysis (bar). See text for 
absolute levels of extracellular glutamate. A: data (means ± SEM; n = 5 per group) 
are expressed as a percentage of the averaged three baseline values prior to 
treatment. B: bargraphs of the areas under the curves, calculated as the 
percentage of change in basal values over time. Data were analyzed by two-way 
(A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple 
comparisons. *P<0.05, compared to controls. 
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4.2. PREFRONTAL CORTEX 
 
4.2.1. Basal extracellular GABA and glutamate levels 
Basal extracellular GABA and glutamate levels, measured in 30 min dialysate 
fractions, were 38.7 ± 3.9 nM and 385 ± 33 nM (n = 22), respectively. In control 
rats, these levels remained essentially stable over the duration of the experiment 
(6 h), with a fluctuation of no more than 5-7%. 
 
 
4.2.2. Effects of intra-PFC KYNA perfusion 
Local perfusion with KYNA (30-300 nM) caused a concentration-dependent 
decrease in extracellular GABA levels. This reduction was already seen in the first 
sample after the introduction of KYNA, and GABA levels gradually returned to 
baseline values after KYNA was removed from the perfusion solution. A 
statistically significant effect was obtained with 100 nM KYNA, and further 
reductions were seen after perfusion with higher concentrations (Figure 25) 
(maximal decrease to 48 ± 7 % of control values at 300 nM KYNA). Statistical 
assessment of the AUC revealed that the effects of 300 nM KYNA exceeded the 
effects of 100 nM KYNA (Figure 25). 
Local perfusion with KYNA (30-300 nM) was also associated with concentration-
dependent decreases in extracellular glutamate levels (Figure 26). A statistically 
significant effect was obtained with 100 nM KYNA, and further reductions were 
seen after perfusion with higher concentrations (Figure 26) (maximal decrease to 
69 ± 8 % of control values at 300 nM KYNA). Statistical assessment of the AUC 
revealed that the effects of 300 nM KYNA exceeded the effects of 100 nM KYNA 
(Figure 26). 
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Figure 25. Effect of kynurenic acid (KYNA) on extracellular GABA levels in the rat 
PFC. KYNA was applied for 2 h by reverse microdialysis (bar). See text for 
absolute levels of extracellular GABA. A: data (means ± SEM; n = 6 per group) are 
expressed as a percentage of the averaged three baseline values prior to 
treatment. B: bargraphs of the areas under the curves, calculated as the 
percentage of change in basal values over time. Data were analyzed by two-way 
(A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple 
comparisons. *P<0.05, **P<0.01 compared to both controls and 30 nM KYNA; 
°P<0.05, °°P<0.01 compared to the effects of 100 nM KYNA. 
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Figure 26. Effect of kynurenic acid (KYNA) on extracellular glutamate levels in the 
rat PFC. KYNA was applied for 2 h by reverse microdialysis (bar). See text for 
absolute levels of extracellular glutamate. A: data (means ± SEM; n = 6 per group) 
are expressed as a percentage of the averaged three baseline values prior to 
treatment. B: bargraphs of the areas under the curves, calculated as the 
percentage of change in basal values over time. Data were analyzed by two-way 
(A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple 
comparisons. *P<0.05, **P<0.01 compared to both controls and 30 nM KYNA; 
°P<0.0 compared to the effects of 100 nM KYNA. 
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4.2.3. Effects of intra-PFC 7-Cl-KYNA perfusion 
As observed in the striatum, intra-PFC perfusion of 7-Cl-KYNA (100 nM) did not 
affect extracellular GABA and glutamate levels. Moreover, co-perfusion with 7-Cl-
KYNA (100 nM) did not influence the reduction in extracellular GABA (Figure 27) 
or glutamate (Figure 28) levels caused by 100 nM KYNA. 
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Figure 27. Effect of 100 nM 7-chlorokynurenic acid (7-Cl-KYNA), perfused alone 
or in combination with 100 nM KYNA, on extracellular GABA levels in the rat PFC. 
Test agents were applied for 2 h by reverse dialysis (bar). A: data (means SEM) 
are expressed as a percentage of the averaged three baseline values prior to 
treatment.  B: bargraphs of the areas under the curves, calculated as the 
percentage of changes in basal values over time. Data were analyzed by two-way 
(A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple 
comparisons. **P<0.01 compared to both controls and 7-Cl-KYNA alone. 
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Figure 28. Effect of 100 nM 7-chlorokynurenic acid (7-Cl-KYNA), perfused alone 
or in combination with 100 nM KYNA, on extracellular glutamate levels in the rat 
PFC. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means 
SEM) are expressed as a percentage of the averaged three baseline values prior 
to treatment.  B: bargraphs of the areas under the curves, calculated as the 
percentage of changes in basal values over time. Data were analyzed by two-way 
(A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple 
comparisons. **P<0.01 compared to both controls and 7-Cl-KYNA alone. 
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4.2.4. Effects of intra-PFC galantamine perfusion 
Intra-PFC perfusion of galantamine (5 µM) did not induce significant changes in 
local extracellular GABA and glutamate levels on its own. This profile of action is 
different from that displayed by the compound in the striatum (see above). When 
galantamine (5 µM) and KYNA (100 nM) were co-infused, extracellular GABA and 
glutamate levels remained unchanged compared to the respective baseline values 
(Figure 29 and 30). 
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Figure 29. Effects of 5 μM galantamine, perfused alone or in combination with 100 
nM KYNA, on extracellular GABA levels in the rat PFC. Test agents were applied 
for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed as a 
percentage of the averaged three baseline values prior to treatment. B: bargraphs 
of the areas under the curves, calculated as the percentage of changes in basal 
values over time. Data were analyzed by two-way (A) or one-way (B) ANOVA and 
subsequent Newman-Keuls test for multiple comparisons. 
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Figure 30. Effects of 5 μM galantamine, perfused alone or in combination with 100 
nM KYNA, on extracellular glutamate levels in the rat PFC. Test agents were 
applied for 2 h by reverse dialysis (bar). A: data (means ± SEM) are expressed as 
a percentage of the averaged three baseline values prior to treatment. B: 
bargraphs of the areas under the curves, calculated as the percentage of changes 
in basal values over time. Data were analyzed by two-way (A) or one-way (B) 
ANOVA and subsequent Newman-Keuls test for multiple comparisons. 
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4.2.5. Effects of intra-PFC ESBA perfusion 
Intra-PFC perfusion of ESBA reduces the extracellular concentration of KYNA (Wu 
et al., 2010). In the present study, perfusion with ESBA (5 mM) increased 
extracellular GABA levels, which reached a peak value 155 ± 11% of baseline 
after 1.5 h (Figure 31). GABA levels gradually returned to control values after 
ESBA was removed from the perfusion solution. Co-application of KYNA (30 nM) 
completely abolished the effect of ESBA (5 mM) on extracellular GABA levels. 
Intracortical perfusion of ESBA (5 mM) also increased extracellular glutamate 
levels. However, this effect reached a peak value 162 ± 9% of baseline after 0.5 h 
(Figure 32) and seems to be less prolonged than that observed measuring GABA 
levels.  
The effect of ESBA on extracellular glutamate levels was neutralized by co-
perfusion of KYNA (30 nM; Figure 32). 
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Figure 31. Effect of 5 mM (S)-4-(ethylsulfonyl)benzoylalanine (ESBA), perfused 
alone or in combination with 30 nM KYNA, on extracellular GABA levels in the rat 
PFC. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means ± 
SEM) are expressed as a percentage of the averaged three baseline values prior 
to treatment. B: bargraphs of the areas under the curves, calculated as the 
percentage of changes in basal values over time. Data were analyzed by two-way 
(A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple 
comparisons. **P<0.01 compared to both controls and (ESBA + KYNA). 
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Figure 32. Effect of 5 mM (S)-4-(ethylsulfonyl)benzoylalanine (ESBA), perfused 
alone or in combination with 30 nM KYNA, on extracellular glutamate levels in the 
rat PFC. Test agents were applied for 2 h by reverse dialysis (bar). A: data (means 
± SEM) are expressed as a percentage of the averaged three baseline values 
prior to treatment. B: bargraphs of the areas under the curves, calculated as the 
percentage of changes in basal values over time. Data were analyzed by two-way 
(A) or one-way (B) ANOVA and subsequent Newman-Keuls test for multiple 
comparisons. **P<0.01 compared to both controls and (ESBA + KYNA). 
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4.2.6. Effects of intra-PFC CNQX perfusion 
Perfusion of CNQX (100 µM), an AMPA/kainate receptor antagonist, did not 
induce significant changes in extracellular GABA or glutamate levels in the PFC 
(Figure 33 and 34). 
 
 
 
Figure 33. Effect of 100 µM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) on 
extracellular GABA levels in the rat PFC. CNQX was applied for 2 h by reverse 
dialysis (bar). A: data (means ± SEM) are expressed as a percentage of the 
averaged three baseline values prior to treatment. B: bargraphs of the areas under 
the curves, calculated as the percentage of changes in basal values over time. 
Data were analyzed by Student’s t-test. 
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Figure 34. Effect of 100 µM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) on 
extracellular glutamate levels in the rat PFC. CNQX was applied for 2 h by reverse 
dialysis (bar). A: data (means ± SEM) are expressed as a percentage of the 
averaged three baseline values prior to treatment. B: bargraphs of the areas under 
the curves, calculated as the percentage of changes in basal values over time. 
Data were analyzed by Student’s t-test. 
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5. DISCUSSION 
 
Once upon a time, KYNA was considered one of the numerous inert tryptophan 
metabolites existing in mammalian urines. Its name, in fact, was coined by Liebeg 
in the second half of the 19th century and means ‘‘acid in dog urines’’. 
Subsequently, its molecular structure was clarified and the compound was 
chemically synthesized at the beginning of the 20th century. This led to a series of 
discoveries that turned out to have significant implications in neuropharmacology 
field. It is now clear that KYNA was the first of the so-called “neuroactive 
kynurenines", a group of metabolically related compounds (see Introduction) able 
to influence brain function. More importantly, it has been demonstrated that KP 
metabolites, including KYNA, play a relevant role not only in brain physiology but 
also as potential causative factors in several devastating brain diseases. As a 
consequence, over the last years there have been intensified efforts to better 
understand the neuromodulatory activity of KYNA under physiopathological 
conditions. 
In the present research, the in vivo effects of KYNA on endogenous extracellular 
glutamate and GABA levels in the striatum and PFC of the awake rats have been 
investigated. Taken together, the present results demonstrated that nanomolar 
(i.e. physiological) concentrations of KYNA significantly and concentration-
dependently influence extracellular glutamate and GABA levels in the both brain 
areas of awake, freely moving rats. They also indicate that the selective NMDAR 
antagonist 7-Cl-KYNA, which is ~20 times more potent than KYNA as an NMDAR 
antagonist but does not inhibit α7nAChR function (Parsons et al., 1997; Hilmas et 
al., 2001), does not reduce glutamate and GABA levels on its own and does not 
modify the KYNA-induced decrease in GABA levels. In addition, co-administration 
of galantamine, a positive allosteric modulator of the α7nAChRs (Lopes et al., 
2007), prevents the KYNA-induced decrease in striatal and PFC glutamate and 
GABA levels, thus suggesting a possible role of α7nAChRs in the interaction 
between KYNA and aminoacidergic transmission in the two brain regions. Finally, 
inhibition of endogenous KYNA production by the KAT II inhibitor ESBA results in 
an augmentation of extracellular glutamate and GABA levels, which is neutralized 
by the addition of KYNA. The results from these acute experiments provide 
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evidence for a bi-directional regulation of extracellular glutamate and GABA levels 
by endogenous KYNA, and may be relevant for our understanding of 
physiopathological role of this neuroactive kynurenine in the brain. The effects of 
KYNA level fluctuations on extracellular glutamate and GABA levels in the rat 
striatum could have functional consequences which partly differ from those due to 
the changes in PFC KYNA concentrations. Thus, in the present paragraph the in 
vivo effects of KYNA on endogenous extracellular glutamate and GABA levels in 
the two brain regions are separately discussed. 
 
 
5.1 Striatum 
The present results firstly confirm that KYNA reduces striatal glutamate levels 
(Moroni et al., 2005; Rassoulpour et al., 2005) and, in addition, demonstrate for 
the first time that this effect is concentration-dependent (30-1000 nM). 
Furthermore, the present findings provide new in vivo evidence that KYNA also 
induces a parallel and concentration-dependent decrease in striatal GABA levels. 
For both neurotransmitters the inhibitory effect was observed at a concentration of 
100 nM used in other studies, and was maximal at 300 nM. 
Since KYNA acts as a non-competitive antagonist of the α7nAChRs, from these 
data it can be reasonably proposed that the reduction of extracellular glutamate 
and GABA levels by low concentrations of KYNA could be mediated by these 
receptors. In according with these results, previous in vivo microdialysis studies in 
rodents revealed that even minor elevations in KYNA levels cause a reduction in 
extracellular glutamate by inhibiting the α7nAChRs located on glutamatergic nerve 
terminals (Carpenedo et al., 2001; Rassoulpour et al., 2005; Konradsson-Geuken 
et al., 2010; Wu et al., 2010). Furthermore, an α7nAChR-mediated inhibition of 
striatal dopamine levels following KYNA perfusion, has also been reported (Wu et 
al., 2007). A KYNA-induced inhibition of GABA release triggered by α7nAChR 
activation in hippocampal cultures has also been demonstrated (Lopes et al., 
2007). 
The modulation of neurotransmitter release by presynaptic nAChRs is the most 
prevalent and well-studied nicotinic role in the central nervous system. It is well 
established that the release of many different neurotransmitters is increased by 
the activation of nAChRs (McGehee and Role, 1995; Role et al., 1996; Wonnacott, 
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1997; Jones et al., 1999; McGehee et al., 1995; Gray et al., 1996; Albuquerque et 
al., 1997; Alkondon et al., 1997; Lena and Changeux, 1997; Picciotto et al., 1998; 
Guo et al., 1998; Radcliffe and Dani, 1998; Luetje 2004; Sher et al., 2004). 
Consistently, exogenous application of a nicotinic agonist often induces an 
increase while a nicotinic antagonist induces a decrease in acetylcholine, 
glutamate, dopamine and norepinephrine release. nAChRs seem to play a role 
also in the modulation of GABA release. In particular, the nAChR α4 and β2 types 
are the most common ones and are widely expressed in the mammalian brain, 
including the striatum (Wada et al., 1989; Colquhoun and Patrick, 1997). The α7 
subunit-containing nAChRs are the next most common (Seguela et al., 1993). 
Recent electrophysiological data have demonstrated the presence of nAChRs on 
GABAergic interneurons in the striatum although the subtypes involved in this 
effect remain unknown (De Rover et al. 2000; Koos and Tepper, 2002). Other 
studies support the presence of α7nAChRs on striatal cholinergic interneurons 
(Azam et al. 2003) as well as on GABAergic interneurons or cell bodies (Kulak et 
al., 2004). Thus, the localization of α7nAChRs into the striatum is consistent with 
the hypothesis that KYNA can modulate striatal transmission by acting on these 
receptors. This view is supported by the data we obtained from the co-application 
of galantamine (5 µM), that acts as a positive allosteric modulator of the 
α7nAChRs, with KYNA 100 nM. Interestingly, the intrastriatal galantamine 
perfusion modestly increased both glutamate and GABA levels. These effects 
could be due to the positive allosteric action on α7nAChRs by galantamine, which 
could lead to an increased acetylcholine-induced excitatory modulation of 
glutamate and GABA levels. This finding is consistent with previous data (Santos 
et al., 2002) suggesting that galantamine, by acting on presynaptic nAChRs, 
facilitates glutamatergic and GABAergic neurotransmission. Nicotinic allosteric 
potentiating ligands, including galantamine, physostigmine, and codeine, 
effectively increase αn7AChRs activation at subsaturating agonist concentrations 
(Pereira et al., 2002). Galantamine is currently used to treat mild-to-moderate 
Alzheimer’s disease (Corey-Bloom, 2003) and has also been tested as an 
adjuvant therapy to improve cognitive function in SZ (Norén et al., 2006; Schubert 
et al., 2006). Although galantamine is recognized as a weak reversible 
cholinesterase inhibitor, its nicotinic allosteric potentiating ligand action seems to 
be an important determinant of its clinical effectiveness (reviewed in Corey-Bloom, 
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2003; Maelicke and Albuquerque, 1996; Pereira et al., 2002). Acting primarily as a 
nicotinic allosteric potentiating ligand, galantamine improves synaptic transmission 
and decreases neurodegeneration, two effects essential for its cognition-
enhancing properties (Santos et al., 2002; Dajas-Bailador et al., 2003; Arias et al., 
2004; Kihara et al., 2004; Zhang et al., 2004). Thus, it has been reported that at a 
concentration favoring its nicotinic allosteric potentiating ligand action, galantamine 
also increased the net charge of choline-evoked on inhibitory postsynaptic 
currents, IPSCs (i.e. GABA release) triggered by activation of αn7AChRs present 
on GABAergic hippocampal neurons (Lopes et al., 2007). 
More importantly, the present results demonstrate that the co-application of 
galantamine and KYNA fully prevents the KYNA-induced reduction in both 
glutamate and GABA levels. This finding is compatible with the hypothesis that 
these effects were mediated by KYNA’s actions at the α7nAChRs. In line with a 
previous study (Lopes et al., 2007), this observation also provides evidence to 
support the functional relevance of the antagonistic interactions between the two 
ligands at α7nAChRs in vivo. In fact, superimposition of the lowest energy 
conformers of galantamine and KYNA revealed a very good fit and shed some 
light on structural differences that could explain the opposite actions that result 
from the interactions of the two compounds with the allosteric potentiating ligand-
binding region on α7nAChRs (Lopes et al., 2007). Other studies, performed in the 
rat PFC, demonstrated the ability of galantamine to prevent both neurochemical 
and cognitive impairments produced by KYNA (Alexander et al. 2012). However, 
we cannot exclude that the ability of galantamine to weakly increase the 
extracellular glutamate and GABA levels could contribute to its action against 
KYNA-induced effects. 
To further support the relevance of the role that KYNA plays in regulating striatal 
glutamate and GABA levels, the present study also demonstrates that the specific 
inhibition of kynurenate synthesis by local perfusion with ESBA increased both 
neurotransmitters in the striatum of awake rats. In this context, it is worth noting 
that previous studies have demonstrated that local PFC perfusion of the selective 
KAT-II inhibitor ESBA causes a reduction in extracellular KYNA levels associated 
with a concomitant increase in extracellular glutamate (Zmarowski et al., 2009; Wu 
et al., 2010; Konradsson-Geuken et al., 2010). Furthermore, in the rat striatum, 
ESBA reduces extracellular KYNA levels and this effect is accompanied by an 
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increase in extracellular dopamine levels (Amori et al. 2009). Thus, our study 
supports the notion that reductions in striatal KYNA formation are functionally 
significant in vivo. In particular, it seems likely that, in the present study, ESBA 
increased glutamate and GABA levels by reducing endogenous KYNA levels. This 
view is further supported by the demonstration that when co-infused with KYNA 
(100 nM), ESBA failed to affect extracellular glutamate and GABA levels. 
Interestingly, unpublished results indicated that ESBA-induced increase in 
extracellular glutamate and GABA levels was also blocked by its co-perfusion with 
a lower (i.e. by itself ineffective) KYNA concentration (30 nM). Taken together, 
these data indicate the existence in the striatum of an inhibitory tone exerted by 
endogenous KYNA on extracellular glutamate and GABA levels.  
Since our investigation has been conducted using microdialysis, it is also 
important to consider that dialysate basal extracellular glutamate and GABA levels 
are derived from both neuronal and glial sources (vesicular or non-vesicular pools) 
(Timmerman and Westerink, 1997; Baker et al., 2002). Neuronal glutamate levels 
in the striatum mainly derived from cortical and thalamic neuron terminals 
(Sirinathsinghji and Heavens, 1989; Parent and Hazrati, 1995), whereas 
extracellular striatal GABA levels derived in part from local interneurons and the 
axon collaterals of the striopallidal and strionigral projection neurons 
(Sirinathsinghji and Heavens, 1989; Parent and Hazrati, 1995). The evidence that, 
under the present experimental conditions, TTX (2 µM), a well-known sodium 
channel blocker, induced only a modest reduction in basal extracellular levels of 
glutamate and GABA, suggests that these levels are derived from both neuronal 
and glial sources. Various studies previously reported that striatal glutamate and 
GABA levels in dialysates are virtually TTX-insensitive and unaffected by the 
depletion of extracellular Ca++ levels (Timmerman and Westerink, 1997). However 
other studies found a partial TTX-sensitivity of basal striatal dialysate glutamate 
and GABA levels (Osborne et al., 1990; Dawson et al., 1995). Based on the TTX-
sensitivity of glutamate and GABA levels under our experimental conditions, it can 
be hypothesized that KYNA exerts its effects on the two neurotransmitters by 
modulating exocytotic processes. However, in view of the clear-cut reduction of 
glutamate and GABA levels seen with KYNA vs TTX, a decrease of glial glutamate 
and GABA levels is likely involved in the decline of these extracellular aminoacid 
levels seen after KYNA perfusion. The demonstration that α7nAChRs are also 
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localized on astrocytes (Pakkannen et al., 2005), supports the possibility that glia 
may likewise play a role in the action of KYNA on extracellular glutamate and 
GABA levels. This view is further reinforced by the observation that when we 
perfused TTX (2 µM) in combination with ESBA, we observed a significant, but 
partial, reduction of the ESBA-induced increase in extracellular glutamate and 
GABA levels. It could be proposed that TTX, by deleting the endogenous 
cholinergic tone on glutamate and GABA neurons, renders ineffective the ESBA-
induced counteraction of the inhibitory tone exerted by endogenous KYNA, 
through α7nAChRs, on extracellular glutamate and GABA levels. 
Taken together, the present experiments clearly indicate that fluctuations in the 
endogenous KYNA levels tonically regulate extracellular glutamate and GABA 
levels in the rat striatum, possibly by acting on local α7nAChRs. Concerning a 
possible mechanism of action, it seems likely that KYNA-induced modulation of 
striatal glutamate levels is mediated by α7nAChRs on cortical glutamatergic 
afferents (Pakkanen et al., 2005). It could be postulated that these presynaptic 
receptors, which can modulate striatal glutamate levels (Kaiser and Wonnacott, 
2000; Marchi et al., 2002), are regulated by astrocyte-derived KYNA, possibly 
through volume transmission (Agnati and Fuxe 2000, Del Arco et al., 2003; Wu et 
al., 2007; Amori et al., 2009). Furthermore, astrocytes, which can release 
glutamate by stimulation of α7nAChRs (Sharma and Vijayaraghavan, 2001; Patti 
et al., 2007), can contribute to this effect. In view of this, it could also be postulated 
that KYNA decreases striatal GABA levels either directly, by interacting with 
α7nAChRs located on GABAergic interneurons, or indirectly by reducing 
glutamatergic excitatory modulation of striatal GABA levels (Figure 35A). In fact, 
numerous studies suggest that a modulation of glutamate release in the striatum 
by α7nAChRs, in turn affects additional neurotransmitter systems including 
monoamines (Kaiser and Wonnacott, 2000; Barik and Wonnacott, 2006) and 
GABA (Dani and Bertrand, 2007). Thus, the activation of α7nAChRs situated on 
glutamatergic afferents is known to modulate extracellular levels of dopamine 
(Segovia et al., 1997) and previous findings suggested that, mainly through 
presynaptically situated AMPA receptors, KYNA-induced reduction in striatal 
glutamate in turn affects striatal dopamine release (Amori et al., 2009). In view of 
these findings, it seems likely that fluctuations in KYNA indirectly regulate 
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extracellular GABA levels in the striatum by initially targeting α7nAChRs on 
glutamatergic nerve terminals or astrocytes (Figure 35B). 
 
 
A 
 
B 
 
 
 
Figure 35. Schematic representation of the possible mechanisms (i.e. direct, 
Panel A; and indirect, Panel B) underlying the kynurenic acid (KYNA)-induced 
modulation of striatal extracellular GABA levels. For details see text. L-KYN = L-
kynurenine, a KYNA bioprecursor. 
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For the sake of clarity, it should be noted that in recent studies KYNA has been 
also proposed as the endogenous agonist of the GPR35 (see Introduction). This 
receptor is expressed in neurons and glia cells and is especially abundant in the 
dorsal root ganglia as well as in cells of the immune system (Wang et al., 2006). 
The binding of KYNA to GPR35 has been hypothesized to decrease intracellular 
calcium with a consequent reduction of the release of the excitatory amino acids 
from glia cells (Moroni et al., 2012). However, controversy remains to be solved as 
to whether it reaches sufficient tissue concentrations to be the endogenous ligand 
(Mackenzie et al., 2011). Although this finding is still in its infancy and the 
existence of GPR35 into the striatum has not been demonstrated, it could be 
speculated that also this mechanism is involved in the observed KYNA-induced 
reduction of striatal glutamate and GABA levels.  
Concerning the possible relevance of the present study, the ability of endogenous 
KYNA to reduce extracellular glutamate levels, together with its antioxidant 
properties, which are related to the compound’s ability to scavenge hydroxyl, 
superoxide anion and other free radicals, support its role as a neuroprotective 
agent. In fact, it is well known that under pathological conditions, the excessive 
stimulation of NMDA receptors leads to an excess of intracellular calcium to 
produce excitotoxicity, a toxic mechanism currently involved in cell death in 
several disorders of the brain (including Alzheimer's disease, stroke, Huntington's 
disease and Parkinson’s disease). In these pathologies an increased 
glutamatergic transmission and mitochondrial metabolic disturbances are primary 
mechanisms turning neuronal cells more sensitive to excitotoxic damage (Kemp 
and McKernan, 2002). Interestingly, decreased KYNA concentrations have been 
reported in the SN pars compacta, putamen and frontal cortex of patients with 
Parkinson’s disease and have been related to the progression of the pathology. 
Decreased KYNA levels have been found in the CSF, striatum and neocortex of 
patients with Huntington’s disease. Furthermore, the activity of KAT, the enzyme 
responsible for KYNA biosynthesis, has been demonstrated to be reduced in the 
striatum of Huntington’s disease patients (Beal et al., 1990; Jauch et al., 1995; 
Guidetti et al., 2004). These alterations have been suggested to be related to the 
development of the disease. Other reports claim increased formation of neurotoxic 
kynurenines such as QUIN and 3-HK levels and marked decreases in KYNA/QUIN 
and KYNA/3-HK ratios within the striatum of patients with low-grade Huntington’s 
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disease. Concordant observations have been made in the murine models of the 
disease. Taken together, these findings indicate that the pharmacological 
manipulations to utilize the anti-excitotoxic properties of KYNA could be effective 
to confer neuroprotection. In line with this view, at preclinical levels the 
pharmacological elevation of endogenous astrocytic KYNA release has been 
proven to be neuroprotective against striatal QUIN toxicity. The genetic ablation of 
KMO, the activation of which results in a harmful shift in kynurenine metabolism 
towards the formation of toxic metabolites, has also been demonstrated to be 
neuroprotective in transgenic yeast and Drosophila models of the disease. More 
recently, the intraperitoneal application of a novel KYNA analogue N-(2-N,N-
dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride resulted in 
a remarkable (30%) increase in survival and improvement in motor performance in 
a transgenic murine model of Huntington’s disease. Although these “kynurenergic 
approaches” to contrast neurodegeneration appear to be promising, the most 
important question that should be addressed is whether the elevation of KYNA 
levels that achieve neuroprotective effects at least in part through suppressing 
synaptic glutamate release can be utilized without compromising cognitive 
functions. Indeed, endogenous elevation of KYNA and the subsequent 
suppression in the presynaptic release of glutamate, and also GABA levels, have 
been linked to decreased performance in a wide range of hippocampus-dependent 
tasks experimentally. Interestingly, also the striatum could be involved in these 
deleterious effects of increased KYNA levels. In fact, an abnormal disposition of 
striatal neurotransmitters, including acetylcholine, dopamine, glutamate and 
GABA, is known to play a major role in the dysfunction of cortico-basal ganglia-
thalamo-cortical circuit, which underlies key aspects of cognition (Havekes et al., 
2011). In this context, recent studies support the hypothesis that the striatum is 
involved in initiating the cognitive deficits associated to SZ (Simpson et al. 2010), a 
mental illness in which a dysfunction in KP seems to play a relevant role (see 
below). 
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5.2 Prefrontal cortex 
The PFC contains glutamatergic and GABAergic afferents (Gritti et al., 2003; Hur 
and Zaborszky, 2005; Rotaru et al., 2005) as well as intrinsic glutamatergic 
pyramidal neurons and GABAergic interneurons, which are connected by multiple 
signaling mechanisms (Tseng and O’Donnell, 2004; Povysheva et al., 2008; 
DeFilipe et al., 2013). Although the complexity of these anatomical arrangements 
has so far precluded a comprehensive understanding of the functional interactions 
between GABAergic and glutamatergic mechanisms in the PFC, it is noteworthy 
that pharmacological manipulations frequently lead to parallel changes in the 
extracellular levels of GABA and glutamate in this brain region (Sanz et al., 1997; 
Abekawa et al., 2000; Frantz et al., 2002; Yamamura et al., 2009). While 
exceptions have been noted (Frantz et al., 2002; Pistis et al., 2002), the KYNA-
related fluctuations in the levels of these two major neurotransmitters in the 
present study were also remarkably similar in both qualitative and quantitative 
terms. In fact, our parallel determination of GABA and glutamate in the same 
microdialysate fractions revealed additional features of the recently described bi-
directional modulation of extracellular glutamate levels by endogenous KYNA in 
the rat brain (Konradsson-Geuken et al., 2010; Wu et al., 2010; Pocivavsek et al., 
2011). Thus, we showed here for the first time that local perfusion of nanomolar 
KYNA reduces glutamate levels in the PFC concentration-dependently, and that 
this effect was not duplicated by either 7-Cl-KYNA or CNQX. Moreover, specific 
inhibition of KYNA neosynthesis caused an increase in extracellular glutamate 
levels, and this effect was prevented by the addition of 30 nM KYNA to the 
perfusion medium. Finally, co-application of galantamine prevented the reduction 
of glutamate levels by KYNA. Taken together, these results demonstrate a close 
coupling between the effects of endogenous KYNA on extracellular GABA and 
glutamate levels in the PFC. 
Our pharmacological data indicate that glutamate receptors are not the primary 
target of endogenous KYNA in the rat PFC in vivo, as demonstrated by the failure 
of the selective NMDA receptor antagonist 7-Cl-KYNA or the selective 
AMPA/kainate antagonist CNQX to duplicate the effect of KYNA. Possible 
alternatives include the α7nAChRs (Hilmas et al., 2001), GPR35 (Wang et al., 
2006), and the aryl hydrocarbon receptor (DiNatale et al., 2010), all of which 
recognize KYNA at concentrations in the high nanomolar to low micromolar range. 
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As α7nAChRs in the PFC, like in other brain regions (McGehee et al., 1995; 
Marchi et al., 2002), are located on glutamatergic nerve terminals where they can 
control glutamate release (Gioanni et al., 1999; Dickinson et al., 2008), and as 
α7nAChRs are expressed and functional in PV-positive (i.e. GABAergic) cortical 
interneurons (Lubin et al., 1999; Alkondon et al., 2000; Krenz et al., 2001), these 
receptors are especially attractive candidates. The present demonstration that 
galantamine, which activates an allosteric site of the α7nAChR that overlaps with 
the site targeted by KYNA (Lopes et al., 2007), neutralizes the effects of KYNA 
also appears to favor this interpretation. However, in line with previous findings 
(Konradsson-Geuken et al., 2010; Wu et al., 2010), and in contrast to the striatum 
(Beggiato et al., 2013), we failed to observe any significant increase in local 
extracellular glutamate and GABA levels when galantamine alone was perfused 
into the PFC. Thus, under basal conditions, glutamatergic and GABAergic 
neurotransmission in the PFC may be less sensitive to α7nAChRs allosteric 
potentiation by galantamine than in the striatum and in other cortical areas 
(Alkondon et al., 2009; Aracri et al., 2010). More generally and of note, KYNA 
does not inhibit α7nAChR function in all situations (Arnaiz-Cot et al., 2008) so that 
definitive identification of its in vivo target(s) clearly requires further detailed 
scrutiny (see Albuquerque and Schwarcz, 2013, for review).  
In the PFC, the majority (65%) of α7nAChRs is associated with dendrites and 
dendritic spines, which are postsynaptic to excitatory axon terminals devoid of 
α7nAChRs (Duffy et al., 2009). These nerve endings, which form a dense network 
of asymmetric axo-dendritic synapses onto prefrontal interneurons, may derive 
from extrinsic neurons (Rotaru et al., 2005). Activation of α7nAChRs can therefore 
modulate cortical GABAergic neurotransmission not only indirectly, i.e. via 
glutamate, but also directly (Thomsen et al., 2009). In addition, since α7nAChRs in 
the PFC are also localized on non-glutamatergic nerve endings (Duffy et al., 
2009), other, complex mechanisms involving α7nAChRs likely also play a role in 
the regulation of prefrontal GABAergic and glutamatergic neurotransmission 
(Couey et al., 2007; Aracri et al., 2010). 
The role of astrocytes, which themselves carry functional α7nAChRs (Duffy et al., 
2011; Shen and Yakel, 2012) and GPR35 receptors (Berlinguer-Palmini et al., 
2013), and are known to control cortical GABA and glutamate neurons (Patti et al., 
2007; Wang et al., 2013), deserves special attention in the context of our study. 
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Furthermore in the cortex as well as in other brain regions, these glial cells contain 
the vast majority of KAT II, the major enzyme responsible for the synthesis of 
rapidly mobilizable KYNA in the brain (Guidetti et al., 2007). Upon neosynthesis, 
astrocyte-derived KYNA is rapidly liberated into the extracellular milieu where it 
can serve as a neuromodulator (Turski et al., 1989; Schwarcz et al., 2012). Here 
we took advantage of this anatomical arrangement to test the hypothesis that a 
reduction in KYNA formation will also influence extracellular glutamate and GABA 
concentrations, albeit in the opposite direction as perfusion with KYNA itself. In 
other words, our experiment was designed to investigate the possible role of 
endogenous KYNA as a bona fide regulator of extracellular glutamate and GABA 
levels in the PFC, as shown in the striatum. To this end, we inhibited astrocytic 
KYNA production by reverse dialysis of the selective KAT II inhibitor ESBA 
(Pellicciari et al., 2008) and confirmed the specificity of the observed increase in 
extracellular glutamate and GABA levels by neutralizing the effect using co-
perfusion of ESBA with minute amounts of KYNA.  
KP metabolism is impaired, resulting in elevated brain and CSF levels of KYNA in 
psychiatric diseases, including SZ (Erhardt et al., 2001; Schwarcz et al., 2001; 
Miller et al., 2006; Sathyasaikumar et al., 2011; Wonodi et al., 2011; Lavebratt et 
al., 2013) and bipolar disorder (Olsson et al., 2012), as well as in relevant animal 
models (Miura et al., 2011; Pocivavsek et al., 2012; McTighe et al., 2013). The bi-
directional modulation of prefrontal GABA and glutamate levels by KYNA is 
therefore not only of obvious physiological relevance but may also be pertinent to 
the etiology of attentional and cognitive deficits observed in SZ and other brain 
diseases. Electrophysiological and imaging studies in patients, as well as post-
mortem assessments of brain tissues, have provided evidence for 
pathophysiologically significant impairments in both GABAergic and glutamatergic 
neurotransmission in psychiatric disorders. In addition, cortical GABA dysfunction 
is one of the most consistently observed abnormality in SZ (Coyle, 2004; Volk and 
Lewis, 2010; Gonzalez-Burgos and Lewis, 2012). As defective cortical GABA and 
glutamate function substantively impairs cognitive processes (Floresco et al., 
2009; Goto et al., 2010; Pehrson et al., 2013; Rompala et al., 2013), and as 
increases in brain KYNA levels in rats adversely affect a variety of cognitive 
functions (Chess et al., 2007; Pocivavsek et al., 2011; Alexander et al., 2012), it is 
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tempting to hypothesize a causal connection between these neurochemical and 
behavioral phenomena. 
Notably, an activation of astrocytes in the PFC of individuals with psychotic illness 
has recently been reported (Feresten et al., 2013) and may be related to the 
increase in prefrontal KYNA levels seen in SZ (Schwarcz et al., 2001). Regardless 
of this potential causal link between structure and function, and assuming that our 
data can be extrapolated to humans, the results of the present study suggest that 
a down-regulation of KYNA formation in astrocytes may not only boost cognitive 
functions in normal individuals, as suggested by the enhanced cognitive behaviors 
seen in KAT II-deficient mice (Potter et al., 2010) and following pharmacological 
KAT II inhibition in healthy rats (Pocivavsek et al., 2011), but may provide special 
benefits in the treatment of cognitive deficits in SZ and other brain diseases. Such 
improvements would be in line with the ability of the specific KAT II inhibitor ESBA 
to elevate the extracellular levels of both GABA and glutamate in the PFC shown 
here. Ongoing studies in the laboratories of Prof. R. Schwarcz are designed to 
reduce KYNA neosynthesis, and thus elevate extracellular GABA and glutamate 
levels in the PFC, by administering the novel, orally active KAT II inhibitor BFF-
816, which has shown promising effects in preliminary experiments (Wu et al., in 
press). 
 
 
5.3. Conclusion 
The ongoing discoveries in the KP field are revealing that this highly conserved 
metabolic machinery plays important regulatory functions in the mammalian brain. 
Excitingly, as we explore the largely unknown role(s) of kynurenines in cell biology, 
we are likely to uncover the functional significance of distinct intracellular 
processes they might influence. As widely reported in this dissertation, changes in 
the levels of circulating kynurenine under pathological conditions can either 
increase (in neurological disorders) or reduce (in SZ) the ratio between neurotoxic 
and neuroprotective KP metabolites in the brain. Although the recent progress in 
understanding the physiopathological role that KYNA could play in the CNS, new 
information is needed to confidently predict the desired physiological effects or 
clinical improvements caused by pharmacological manipulations of this 
“neuroactive kynurenine” brain levels. The work described in this dissertation 
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contributes to improve our understanding of endogenous KYNA functions in the 
CNS, and especially in cognitive functions. The main finding we obtained is the 
demonstration that fluctuations in KYNA levels bi-directionally modulate striatal 
and prefrontal GABA and glutamate levels and these effects may be pertinent to 
the etiology of attentional and cognitive deficits observed in SZ and other brain 
diseases. In addition, the ability of the compound to reduce striatal glutamate 
levels at physiological concentrations, may be relevant to further support the 
protective action that KYNA exerts against neurodegenerative diseases. Thus, the 
manipulation of KYNA levels and, in particular the ratio between KYNA and 
“neurotoxic” kynurenines seem to be promising for the therapy of different CNS 
disorders (Figure 36). However, further studies are necessary to confirm that the 
interventions with specific “kynurenergic” drugs must be carefully tailored to 
achieve the intended benefit and avoid harmful outcomes. If the contribution of 
KYNA in the pathogenesis of CNS disorders will be confirmed along with the 
possibility to safely manipulate endogenous KYNA levels, kynurenergic 
manipulations will offer novel therapeutic tools for these severe debilitating 
diseases in the future. 
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Figure 36. Targeting brain kynurenines pharmacologically: focus on KAT II and 
KMO. As KAT II and KMO are directly responsible for the formation of KYNA and 
3-HK, respectively, specific inhibitors of these enzymes can be used to manipulate 
the ratio between these two neuroactive metabolites pharmacologically. Increases 
in the KYNA:3-HK ratio are desirable in neurodegenerative diseases such as 
Huntington’s disease, which present with an excess of neurotoxic 3-HK (and 
QUIN) in the brain. Conversely, lowering of the KYNA:3-HK ratio in the brain will 
improve cognitive capabilities, providing special benefits in diseases such as 
schizophrenia, which show enhanced brain levels of KYNA 140. In the normal 
brain, fluctuations in the KYNA:3-HK ratio will have moderate effects on neuronal 
viability and cognition, limited to the physiological range. Pharmacological 
interventions with specific “kynurenergic” agents, such as KAT II or KMO 
inhibitors, should therefore be tailored to achieve the intended benefits and 
minimize potentially harmful consequences. The gray areas indicate transition 
zones between the physiological range and pathologies. 
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